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Design of a multiplex PCR assay for the detection of Neisseria
sonorrhoeae.

By Elizabeth O’ Callaghan.

Abstract
The incidence of N. gonorrhoeae infections in Ireland has been steadily
increasing since 2003. Culture is currently the preferred method of diagnosis,
however the sensitivity of culture can be low. In recent years there has been increased
interest in non-culture techniques such as polymerase chain reaction (PCR). Many of
the PCR assays available have been shown to cross-react with commensal organisms,
producing false positive results. This study aimed to improve the detection of N.
gonorrhoeae by designing a multiplex PCR assay that used two N. gonorrhoeae genes
as targets, thereby providing dual detection and confirmation of a positive result. PCR
primers were designed to detect two N. gonorrhoeae genes, namely porA and pgil.
Primers for an internal control were also designed. The V. cholerae ompW gene was
chosen as the target for the internal control. The DNA of 51 organisms including 33
N. gonorrhoeae isolates, seven N. meningitidis isolates, two group B Streptococcus, a
group A Streptococcus, an Enterococcus spp, a Coagulase negative Staphlycoccus
and a Klebsiella pneumoniae were tested using the multiplex PCR assay. All 33 N.
gonorrhoeae isolates were successfully detected by the assay while none of the non
gonococcal isolates were detected. The assay therefore showed a specificity and
sensitivity of 100%. The limit of detection was 5ng of DNA for this assay. This
multiplex PCR assay therefore offers a sensitive and specific assay suitable for the
detection of N. gonorrhoeae, and offers real potential for diagnostic use.
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1.0. Introduction.

1.0 Introduction
The organism Neisseria gonorrhoeae (N. gonorrhoeae) is a highly infectious
pathogen, which is transmitted either through sexual contact or parentally when a
neonate passes through the birth canal of an infected mother (Todar, 2004). It
colonises and infects the columnar epithelial cells on the surface of the genital tract
and also the mucosal surfaces of the anorectum, the pharynx and the eye (Tapsall,
2001). It often evades the host defences by using antigenic variability. Culture is
considered the ‘gold standard’ for diagnosis of N. gonorrhoeae infection. Its
fastidious nature, however, presents a number of challenges for the culture of this
organism. Various media, both selective and non selective, are used to culture N.
gonorrhoeae. It has been shown that the ability of different media to support the
growth of N. gonorrhoeae is variable and is affected by factors such as serotype,
auxotype and sensitivity of the organism to vancomycin (Young & Moyes, 1996).
Transport swabs, with or without charcoal, are used to sustain gonococci (Ng &
Martin, 2005). It has also been shown that the recovery of colonies is significantly
reduced after only six hours (Farhat et al, 2001, Arbique et al, 2000, Wade & Graver,
2005).

1.1. History and Taxonomy:
Neisser first described N. gonorrhoeae in 1879 in the pustular exaudate from
a patient suffering from gonorrhoea. It was grown in pure culture in 1885 and was
then established as the causative agent of gonorrhoea using human volunteers in order
to fulfil Kochs Postulates (Todar, 2004). It is a Gram-negative aerobic organism and
is typically seen on microscopy from urethral and endocervical swabs as Gram-

negative intracellular kidney-shaped diplococci (Ng & Martin, 2005). Other
characteristics, which may be used to identify this organism in the laboratory include,
the production of oxidase and catalase, and failure to grow on nutrient agar. It belongs
to the family Neisseriaceae and is a member of the Neisseria genus (Table 1.1). It is
very closely related to and possibly evolved from, another closely related pathogen.
Neisseria meningitidis (Feavers & Maiden, 1998, Whiley et al, 2006). There is a
sequence homology of between 80 and 90% between the genomes of these two
organisms (Chaudhry et al, 2002). There is also considerable sequence homology
with other Neisseria species. For example, most of the virulence genes found in
Neisseria gonorrhoeae are also found in N. lactamica which is a commensal organism
not generally associated with infection (Snyder & Saunders, 2006). Any PCR
detection assay used to distinguish these organisms must be very carefully designed.
Neisseria gonorrhoeae is a relatively fragile organism; it is susceptible to temperature
changes, drying, ultra-violet light, and other environmental conditions. Humans are
the only reservoir of N. gonorrhoeae (Fletcher & Gordon, 1990). As a result there are
no animal models available in which its pathogenesis can be studied.
Table 1.1. Neisseria species: normal habitat and clinical significance (Brenner et al, 2005).
Neisseria species
N meningitidis

N gonorrhoeae
N
N
N
N
N

canis
animalis
mucosa
cinera
sicca

N lactamica
N flavesences
N polysaccharea

Normal habitat
Upper respiratory tract,
pharynx.
CSF, Blood.
Rectum, urogenital tract,
pharynx.
Canine pharynx
Guinea pig pharynx.
Nasopharynx.
URT, endocervix, rectum.
Nasopharynx, saliva,
sputum.
Nasopharynx.
Respiratory tract.
CSF (rare)
Nasopharynx.

Commensal/pathogen
Commensal
Pathogen
Pathogen
Commensal
Commensal
Occasionally pathogenic.
Commensal
Opportunistic pathogen.
Rarely pathogenic.
Commensal
Pathogen
Commensal

1.2 Clinical presentation of gonorrhoea:
Infections with N. gonorrhoeae may present as a broad range of symptoms
and can affect the urogenital, anorectal, pharyngeal and conjunctival areas. In severe
cases the infection may become disseminated causing meningitis, endocarditis and, in
women, pelvic inflammatory disease (P.I.D) (Da Ros & da Silva Schmitt, 2008,
Ghosh et al, 2004).
The urogenital tract is the most common site of N. gonorrhoeae infection.
Infection in men usually occurs as acute urethritis, often accompanied by purulent
discharge (Edwards & Apicella, 2004). N. gonorrhoeae infection may also cause
epididymitis in men, which may present as unilateral testicular pain without discharge
or dysuria (Nusbaum et al, 2004).
In women infection can affect the endocervix, and if an ascending infection
develops, the organism can cause P.I.D. (Hook & Handsfield, 1990). This occurs in
between 10 and 20% of cases (Merck, 2005). Symptoms of A. gonorrhoeae infection
in women include odourless vaginal discharge and vaginal bleeding, particularly after
intercourse. Patients with P.I.D. may experience severe abdominal pain with a high
fever. P.I.D. may result in infertility in 15% of cases (Miller, 2006) and it may also
result in ectopic pregnancy and chronic pelvic pain. Many women, however, display
no symptoms of the infection. They therefore may become reservoirs of the organism,
resulting in further spread of the infection in the community (CDC, 2007b). This
ability of N. gonorrhoeae to cause asymptomatic infections is also critical to its long
term survival in the human host (Tapsall, 2001).
Anorectal infections are most common in women, and in men who have sex
with men (M.S.M). These infections are often asymptomatic but when symptoms are
present they may include anal pruritis and mucopurulent discharge, usually with a

bowel movement. Pharyngeal infection may occur after orogenitial exposure.
Symptoms are generally mild or absent, and untreated cases often resolve
spontaneously (Miller, 2006).
N. gonorrhoeae may also cause ophthalmia neonatorum. This occurs as a
result of the neonate being exposed to infected cervical exudates during delivery. If
left untreated it can cause perforation of the globe of the eye and blindness. Almost all
genital and pharyngeal gonococcal infections in children are caused by sexual abuse
(Charles, 2005).
N. gonorrhoeae may enter the bloodstream causing a disseminated infection
(Ghosh et al, 2004). Disseminated infection is the most common complication of
untreated gonorrhoea, and in rare cases this can result in meningitis (Ross, 1996).
Other clinical manifestations of disseminated infection, which occur in rare cases,
include septic arthritis, skin lesions, endocarditis and epidural abscesses (Rice, 2005).
Infection with N. gonorrhoeae also has a number of other serious
consequences for the patient. It has been shown for example, that N. gonorrhoeae has
the capacity to enhance HIV-1 infection (Zhang et al, 2005).

1.3 Treatment of Neisseria gonorrhoeae infection:
N. gonorrhoeae infections are generally treated successfully with
antimicrobial agents. The antimicrobial agent used depends on the site of the
infection, and whether or not it has disseminated. Antimicrobials used include
cefixime, ceftriaxone, ciprofloxacin, orofloxacin, and ampicillin. There are treatment
guidelines available from the Centres for Disease Control and Prevention (C.D.C.),
for the United States and from www.guideline.gov in the United Kingdom
(Workowski & Berman, 2006; Bignell et ah 2005). These guidelines recommend the

use of ceflxime or ceftriaxone for the treatment of uncomplicated anogenital
infections in adults. Spectinomycin may be used as an alternative therapeutic option
for people who cannot tolerate cephalosporins. However, this option is expensive and
has limited effectiveness for the treatment of pharyngeal infections (Workowski et al,
2008). Since the early 1990s there has been an emergence of quinolone-resistant N.
gonorrhoeae particularly in Asia and among MSM. As a result of continuing
increased resistance to fluoroquinolones (figure 1.1.) the CDC guidelines were
updated in 2007 to recommend that they should no longer be used to treat any patient
group (CDC, 2007). Resistance to many of the drugs used to treat gonococcal
infection has emerged over the past number of years (W.H.O., 2003). There are no
national data available for the antimicrobial resistance rates of A. gonorrhoeae in
Ireland. However the resistance rates tor the U.K. from 2006 are summarised in figure
1.2. (GRASP steering group, 2007). It is very important that the antimicrobial therapy
should take account of local patterns of antimicrobial sensitivity to N. gonorrhoeae
(Bignell, et al 2005).

1«1 1992

1993

199*

1995

1996

199?

1998

1999 3000 2001 2002 3003 200* 2005 3006

V'&ar

* Data for 2006 are preliminary (January—June only).
Demonstrating ciprofloxacin minimLim inhibitory concentrations (MICs) of

^0.1 25—0.500 ^/mL.
^Demonstrating ciprofloxacin MICs of >1.0 /jg.>mL.

Figure 1.1. Percentage of A. gonorrhoeae isolates with intermediate resistance or
resistance to ciprofloxacin in the US between 1990 and 2006. (CDC, 2007, HSPC,
2006)

Antimicrobial resistance of N. gonorrhoeae (U.K.

2006).
40
S 35
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S 25
■% 20
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Figure 1.2. Antimicrobial
resistance of N.
gonorrhoeae in the U.K.
2006 (GRASP steering
group, 2007)

Although researeh is ongoing, to date no effeetive gonocoeeal vaceine has
been developed. A number of eomponents of the gonoeoceal surfaee strueture have
been investigated as possible vaccine eandidates, without sueeess. This is largely
because many of these struetures are variably expressed and they also display
antigenic heterogenity, making it very difficult to design an effeetive vaecine
(Tapsall, 2001). There are a number of mechanisms by which antigenic variation
occurs in Neisseria species. These inelude homologous reeombination, posttranslational modifieation, and slipped-strand mispairing during DNA replieation, and
transeription (Hamrick et al, 2001, Murphy et al, 1989, Wilson et al, 2002).
Homologous recombination is used to shuffle the antigenie makeup of the type IV
pilus of N. gonorrhoeae. There is generally one expression loeus {pilE) containing a
functional pilin gene in the N. gonorrhoeae genome and multiple silent loci {pilS)
containing one or more partial or silent gene copies loeated in other parts of the
genome. Pilin antigenic variation involves recombination between the pilS eopies and
the pilE loeus resulting in a newpilE gene. This results in a different pilin produet
(Hamrick et al, 2001). Occasionally, recombination errors oceur resulting in an on/off
phase variation. Slipped-strand mispairing is used for on/off phase variation of some
outer membrane proteins (Murphy et al, 1989). These genes eontain a run of five
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nucleotide repeat sequences (CTTCT). During DNA replication mispairing can occur,
resulting in strand slippage, which results in the incorporation of errors in the
daughter chromosome (Wilson et al, 2002).
It appears that there is no natural or acquired immunity to gonococcal
infection (Kihlstrom & Danielsson, 1994). However studies have shown that
colonisation by other Neisseria sp. particularly N. lactamica, can contribute to the
natural development of immunity to N. meningitidis. It is thought that this natural
immunity is due to responses against lipooligosaccharides (L.O.S.) and outer
membrane proteins (O.M.P.) which are also found in commensal Neisseria (Sanchez
et al, 2002). These structures have been shown to be important in the adhesion of
gonococci to epithelial cells during infection (Grassme et al, 1997, Edwards &
Apicella, 2002). It would, therefore, be interesting to investigate whether a similar
immune response could be generated that would be protective against N. gonorrhoeae
infection.

1.4 Epidemiology of Neisseria gonorrhoeae:
The total number of sexually transmitted infections (STI), reported in Ireland
to the Health Protection Surveillance Centre (HPSC) has been increasing steadily in
recent years. The incidence of STI has risen by 313.3% between 1994 and 2004.
Gonorrhoea is no exception to this trend with a 45.2% increase in notifications
recorded between 2003 and 2004 and a further increases of 26.7% between 2004 and
2005 and 26% between 2005 and 2006 (figure 1.3.) (HSPC, 2006; HPSC, 2008;
HPSC, 2005). Similarly in the United States, gonorrhoea is the second most
commonly-reported notifiable disease. Although there has been a decrease in reported
cases of gonorrhoea since the 1970s the numbers have started to increase again

according to the 2004 and 2005 figures (www.cde.gov/std/stats/gonorrhea.htm. 2007).
A study examining data collected in STI clinics in England in 2003, found that the
highest rates of infeetion oceurred in women aged between 16 and 19 years and in
men aged between 20 and 40 years (Bozicevic et al, 2006). In Ireland in 2005, the
highest rates of infeetion oeeurred in people aged between 20 and 29 (HSPC, 2006).
Approximately 62 million new inteetions with N. gonorrhoeae occur annually
worldwide (W.H.O., 2001). The rates of gonorrhoea vary greatly among eountries in
the developed and the developing world. The highest rates are in South and SouthEast Asia, sub-Saharan Africa and Latin America. These figures show that
gonorrhoea remains an important and relatively eommon infeetion.
Notifications of gonorrhoea in Ireland.
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Figure 1.3. Notifieations of A. gonorrhoeae infections in Ireland 19992006 (HPSC, 2008, HSPC, 2006).

1.5 Laboratory diagnosis of Neisseria gonorrhoeae:
1.5.1. Culture.
Traditionally, diagnosis of gonorrhoea requires eulture on selective media, or
the observation of Gram-negative intraeellular bacteria on microseopy. The seleetive
media that are used to grow N. gonorrhoeae, usually consists of a GC agar base whieh

10

is an agar base specially formulated to encourage the growth of Neisseria species, or
Columbia agar which is a multi-purpose medium suitable for the culture of fastidious
organisms (Oxoid, 2008). This is supplemented with either lysed or chocolatised
horse blood, or another non-blood-based supplement. Selective media contain
antimicrobial agents such as vancomycin or lincomycin to suppress normal flora and
to allow the growth of N. gonorrhoeae. The media should be incubated at 37°C in
CO2 for 48 hours (Bignell et al., 2006). To date, bacterial culture remains the ‘gold
standard’ for the definitive diagnosis of N. gonorrhoeae infection (Whiley et al, 2006;
Whiley et al, 2004; Young et al, 2003; Tapsall, 2001). The culture method is
relatively inexpensive and, under appropriate conditions, has a sensitivity of between
80 and 95% in symptomatic infections (Chaudhry et al, 2002). Its sensitivity however
may fall as low as 50% for females with chronic infection when compared to Nucleic
Acid Amplification Techniques (NAATs) (Whiley et al, 2006). When all suspect
colonies are identified further using biochemical or immunological tests culture has a
specificity of 100% (Bignell et al, 2006).

Figure 1.4. Recovery of 30 strains of N. gonorrhoeae from charcoal
transport medium stored at ambient temperature and 4°C. (*NR, none
recovered.) (Wade & Graver, 2005).
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There are many disadvantages to the diagnosis of gonorrhoea by culture
methods, especially in settings where optimisation of culture is difficult. Problems
with sample transport and storage may influence the sensitivity of cultures (Wade &
Graver, 2005). This study by Wade and Graver performed using 30 clinical samples
held at ambient temperature (AT) and at 4°C, showed that at 24 hours there was
decreased recovery of the strains held at AT and at 48 hours there was decreased
recovery of the strains at AT and at 4°C (figure 1.4). Other factors, which may also
affect the sensitivity of culture methods include poor sampling technique, inhibition
of growth by components of culture media, failure to detect vancomycin-sensitive
strains and the time taken for investigations to be completed, typically between 48 and
72 hours (Chaudhry et al, 2002, Mayta et al, 2006). Factors such as these have
resulted in the replacement of traditional culture methods with nucleic acid detection
tests in many laboratories, especially for example, in remote areas of Australia, where
there may be a significant delay in the transporting of samples to the laboratory
(Smith D.W. et al, 2005).

1.5.2.0. Non-culture methods of detection for A. gonorrhoeae.
Various non-culture diagnostic tests such as direct immunotluorscence assay,
enzyme immunoassay and nucleic hybridisation have been developed (Ison et al,
1985, Schachter et al, 1984). In addition, various different nucleic acid detection
assays have been described for the detection of Neisseria gonorrhoeae DNA (Table
1.2). These include both in-house and commercially-available assays. Ligase chain
reaction (LCR), polymerase chain reaction (PCR), and strand displacement
amplification (SDA), all specifically amplify small quantities of DNA, and can also
detect the presence of non-viable organisms.
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Table 1.2. A summary of some of the NAAT assays which have been
described to detect N. gonorrhoeae DNA.
NAAT Assay

In-house/ commerical

Reference.

PCR targeting the carbamoylphosphate synthase subunit A (carA)
gene.

In-house.

(Mayta et al, 2006)

Multiplex PCR targeting the 23 S
rRNA and mpA (Neisseria spp.) and
orfl gene (N. gonorrhoeae).

In-house.

(Chaudhry et al, 2002)

Two real-time PCR assays targeting
the cppB gene

In-house.

(Tabriz! et al, 2004)

Real-time PCR targeting porA
pseudogene.

In-house.

(Whiley et al, 2004)

Abbott m2000 CT/NG assay

Commercial.

(Marshall et al, 2007)

Real-time PCR targeting opa genes.

In-house.

(Geraats-Peters et al,
2005)

Ligase chain reaction targeting opa
genes.

Commercial.

(Young et al, 2003)

Real-time PCR targeting porA
pseudogene.

In-house.

(Hjelmevoll et al, 2006)

Roche PCR targeting 16S rRNA
gene.

Commercial.

(Van Dyck et al, 2001b)

BDProbe Tec SDA targeting Pivf^g
gene.

Commercial.

(Palmer et al, 2003)

The sensitivity of any method depends on many variables, including the time
taken to transport the specimen to the laboratory, the type of specimen involved and
the type of transport medium used, as well as the culture conditions used. In the case
of nucleic acid detection assays the conservation and stability of the target DNA
sequence have a major impact on the sensitivity of the method. It has been shown that
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the sensitivity ofNAAT compare favourably with culture methods (table 1.3). This
increase in sensitivity in comparison to culture as well as the availability of automated
commercial systems has meant many laboratories throughout the world have moved
from the traditional culture methods to these new faster and more sensitive methods in
order to improve the diagnosis and control of gonorrhoea. Some of the commercial
systems available are listed in table 1.2.

Table 1.3. Sensitivities of various NAAT assays for the detection of N.
gonorrhoeae ( Van Dyck et al, 2001a; Van Dyck et al, 2001b; Young et al, 2003,
Lowe et al, 2006; Mayta et al, 2006).
Diagnostic technique.

Sensitivity (%).

LCR

88.9-94.5

SDA

88.9-94.5

PCR

86.7- 100.

Culture

46.9-81.3

Note: LCR - Ligase chain reaction. SDA - Strand displacement amplification.
PCR - Polymerase chain reaction.
There are, however, many drawbacks to these N.A.A.T. Many of these assays
experience difficulties regarding specificity. Many of the assays produce false
positives with certain non-pathogenic Neisseria species such as N. cinerea, N.
subflava, N. flavescens, N lactamica, N. sicca as well as with lactobacilli. (Farrell,
1999; Palmer et al, 2003). Studies have shown false positive results when using the
LCR, BDProbe Tec and Amplicor assays (Tabrizi et al, 2004; Palmer et al, 2003).
These problems with specificity ofNAAT may be due to intra- and interspecies
genetic recombination which occurs between members of the Neisseria genus. (Linz
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et al, 2000). It is extremely important that any assay used by a laboratory to detect N.
gonorrhoeae is both highly sensitive and specific because any misdiagnosis can have
serious social, legal and physiological ramifications for the patient as well as public
health implications (Whiley et al, 2004, Unemo et al, 2007, Whiley et al, 2006,
Martin et al, 2007). The genes which are to be targeted by any of the NAAT assays
must be carefully selected. For example, a number of assays, both commercial and “in
house” have been developed targeting the cppB gene, which is located on a plasmid in
N. gonorrhoeae. It was later shown, that a subtype exists that lacks the cppB gene
(Lum et al, 2005), and that cppB gene sequences are also found in other Neisseria
spp. (Palmer et al, 2003). Therefore, assays targeting this gene for the detection of N.
gonorrhoeae may produce false positive and false negative results. As outlined in
table 2 some assays target opa genes. However variation of these genes is known to
evolve rapidly (Viscidi & Demma, 2003). Genes such as housekeeping genes that
code for core metabolic proteins are more likely to be highly conserved across a genus
and thus would present a more stable target for a NAAT assay (Perez-Losada et al,
2005).

1.5.2.1 Current use of NAAT assays.
As already outlined, there are many advantages and disadvantages of using
NAAT such as PCR when compared to the current gold standard of culture. The
sensitivity of NAAT if designed properly, can far exceed the sensitivity of culture
especially if the samples are not taken in an STI clinic, where optimum specimen
collection is most likely with rapid transport to the laboratory. However due to the
less than optimum specificity of NAAT assays many laboratories use a second
confirmatory assay targeting a different gene in order to confirm a positive diagnosis
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and to reduce the possibility of reporting false positive results. The Public Health
Laboratory Network in Australia recommended in a report in 2005 that all screening
assays, both in-house and commercial, that are positive, should also be positive on a
reliable supplemental assay before a positive result is reported (Smith D.W et al,
2005). However, the need to perform a confirmatory assay greatly reduces the costeffectiveness of NAAT, as these assays can be comparatively costly (Stanley & Todd,
2005).

1.5.2.2. Use of NAAT assays to detect antimicrobial resistance.
An ideal assay would not only detect the presence of N. gonorrhoeae
accurately in a sample but would also provide information regarding the antimicrobial
susceptibility of the organism. None of the NAAT assays listed in table 1.2. are
capable of providing any antimicrobial resistance data. It would be difficult to design
an assay capable of detecting N. gonorrhoeae and providing comprehensive
antimicrobial data as there are a wide range of resistance mechanisms found in N.
gonorrhoeae (table 1.4).
Table 1.4. A summary of some of the genes that confer resistance by N. gonorrhoeae
to commonly-used antimicrobial agents.

Antimicrobial

Gene affected

Reference

B lactams

Pen A
Pon A
Gyr A
Par C

(Ameyama et al, 2002,
Tanaka et al, 2006)
(Ameyama et al, 2002, Li
et al, 2002, Ng et al, 2002,
Katsumi et al, 2004,
Katsumi et al, 2006)
(Tanaka et al, 2006,
Zarantonelli et al, 1999)
(Tanaka et al, 2006, Hu et
al, 2005)

Quinolones

Azithromycin

Mtr R

Tetracycline

Pen B
Rps J
Mtr R
Pen A
Mtr R
Pen B

Cephalosporins

(Tanaka et al, 2006)
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I.5.2.3. Design of a NAAT assay using bioinformatic tools available online.
All of the bioinformatic tools needed to design a NAAT assay are freely
available for use through the Internet. The Entrez database search system is a
powerful search engine that allows the search of many discrete health sciences
databases at the national centre for biotechnology centre website
(http://www.ncbi.nlm.nih.aov/sites/aquervT Using these databases it is possible to
gain access to over 570 complete microbial genomic sequences via entrez genome
(http://www.ncbi.nlm.nih.aov/sites/entrez?db=aenomeT The entrez nucleotide
database can be used to obtain the nucleotide sequence of a gene and the position of
that gene in a sequenced genome
(http://www.ncbi.nlm.nih.aov/sites/entrez?db=nucleotideT In addition, the Basic
Local Alignment Search Tool (BLAST) programmes may be used to perform
sequence similarity searches against a variety of databases
(http://blast.ncbi.nlm.nih.aov/Blast.cgiT This allows the determination of whether a
gene is conserved across available sequenced or partially sequenced genomes or
whether a sequence within a gene is unique to that gene (Wheeler et al, 2008). The
Primer 3 programme is a web-based programme freely available from the Whitehead
Institute for Biomedical Research, Cambridge, MD, USA,
(http://fokker.wi.mit.edu/primer3/input.htmT This programme suggests potentially
suitable primers from a DNA sequence inputted by the user. These bioinformatic tools
are very useful when selecting a NAAT gene target.

1.6 Conclusion.
As outlined in table 1.2, there are a number of NAAT assays available
commercially. Each of these assays have been demonstrated to be less than optimally
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specific. All of the “in-house” assays listed in table 1.2. have not been extensively
evaluated using isolates from different populations. As a result there in no widelyused satisfactory NAAT for the detection of N. gonorrhoeae described in the
literature currently. As already discussed, many of the problems experienced by the
available assays are a result of the tendency of members of the Neisseria genus to
engage in intra and interspecies genetic recombination. This results in the sharing of
genetic information between commensal and pathogenic species. To rely on a single
target gene to remain completely conserved within the entire population of N.
gonorrhoeae would therefore appear unwise. The use of a second confirmatory assay
or the inclusion of a second target gene located in a different part of the genome
would ensure the specificity of the test. This would reduce the possibility of a false
positive or a false negative result.
It is important that accurate and sensitive diagnostic services are available to
patients, particularly as the incidence of A. gonorrhoeae is increasing in many
countries. This is particularly important because N. gonorrhoeae can cause
asymptomatic infections and is associated with serious long-term side effects such as
PID and ectopic pregnancy. Reductions in disease rates have been demonstrated when
improved diagnostic facilities have been introduced even in the absence of any
changes in therapeutic regimen or in behaviour (Miller P.J. et al, 1999). Any
reduction in disease rates would have major benefits for population health. It is
therefore imperative that this infection is diagnosed as early as possible to prevent the
development of long-term side effects and to reduce the risk of spreading the
infection.
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2.0 Aims and objectives.
The aims of this project were:
•

To design a multiplex PCR assay for the detection of N. gonorrhoeae.

•

To incorporate two or more N. gonorrhoeae-specific targets, and an internal
control in the assay.

•

To evaluate the assay designed by testing it using a collection of isolates of
Neisseria spp. to include N. gonorrhoeae and N. meningitidis clinical isolates
and N. gonorrhoeae ATCC 3126, N. lactamica ATCC 23970, N. sicca ATCC
29X93, N. flavescens^CTC 3191 and A. cineraNiClC 10294.

•

To evaluate the novel assay by testing it against a collection of non-Neisseria
spp. that might be expected to be found alongside N. gonorrhoeae in clinical
samples. These organisms included a group A Streptococcus, a group B
Streptococcus, an Enterococcus spp, a Coagulase fiegative staphlycoccus and
a Klebsiella pneumoniae.
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3,0 Materials and Experimental Methods.
3.1 Materials.

3.1.1. Collection of organisms.
•

A total of 49 organisms were collected.

•

Clinical isolates comprised 43 organisms which had been routinely isolated
in the Microbiology Department Cork University Hospital (C.U.H.) and
stored for routine research purposes. These included 33 strains of N.
gonorrhoeae, six N. meningitidis isolates and one of each of the following
isolates: a group B Streptococcus, an Enterococcus spp, a Coagulase
negative staphylococcus and a Klebsiella pneumoniae. These isolates were
consecutively numbered as they were received with the prefix CUH, eg
CUH 1, CUH 2 etc. It should be noted that these isolates were deemed the
property of the Microbiology Department and that no patient rights were
infringed. The isolates were not linked to the original patient samples.

•

There were five control isolates used. These included N. gonorrhoeae ATCC
3126, N. lactarnica ATCC 23970, N. sicca ATCC 29193, N. flavescens
NCTC 3191 and A. cinera NCTC 10294.

•

One “in-house” N. meningitidis control strain was included in the study
collection.

•

The DNA of a group A Streptococcus and a group B Streptococcus were
provided by Rachel Kiely Microbiology Department, CUH.

•

A single isolate of V. cholerae from C.U.H. archives was used as an internal
control.
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3.1.2 Storage of isolates.
•

Vials containing threaded beads in a cryopreservative fluid (Technical
Service consultants Ltd. Lancashire U.K.),

•

Brucella broth with glycerol was prepared using:
o Brucella broth powder (BBL^^) (Becton Dickenson & Co. Le
Pont de Claix France): 2.8g suspended in 100ml purified H2O.
o Glycerol: 45ml the Brucella broth suspension was mixed with
15ml glycerol.
o This was aliquoted in 0.5ml volumes into l.Oml microtubes
(Sarstedt, Germany).

3.1.3 Identification of organisms.
•

Gram stain reagents (Bios Europe Lancashire. U.K.):
Crystal violet.
Grams iodine.
Acetone.
Neutral red.

•

Oxidase PYO-test (Medical wire & equipment Co (Bath) Ltd. Wiltshire.
U.K.).

•

A hydrogenperoxide (H2O2) solution.

•

API NH, API 20E, biochemical identification kits, (Biomerieux® SA.
Marcy L’Etoile. France).

•

DNase agar. (Oxoid Ireland c/o Fannin Healthcare, Dublin)

•

Kanamycin Aesculin Azide Agar (KAA), (Oxoid).

•

Streptex ® (Remel Europe Ltd. Kent. U.K.).
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3.1.4. Extraction of DNA.
•

Roche® High Pure Template Preparation Kit (Roche Diagnostics
Mannheim, Germany).

•

Sterile water.

•

1.5 ml eppendorf tubes.

•

Physiological buffered saline (PBS).

•

Lysozyme (Sigma-Aldrich, Germany).

•

Absolute isopropanol.

•

Absolute ethanol.

3.1.5. Quantative analysis of extracted DNA.
•

Nanodrop 1000 spectrophotometer (Thermo Scientific Wilmington DE,
USA).

3.1.6. Qualitative analysis of extracted DNA.
•

Agarose powder (Sigma-Aldrich).

•

DNA Molecular weight marker Grade III: 0.12-21.2 kbp (cat no. 528552) by
Roche Diagnostics®.

•

Sterile lOOpl eppendorf tubes.

•

Glycerol loading dye prepared using:
6.6ml glycerol.
3.3ml lOX TAE.
lOOpl 10% Bromophenol Blue (Aldrich Chemical Co
Ltd. England.) provided at a concentration of 0.1 g BPB
powder in 1 ml sterile water.
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•

Ethidium Bromide (EtBr) stock solution: One ethidium bromide tablet
dissolved in 10ml H2O for final concentration of lOmg/ml, and subsequently
stored in the dark, (Sigma-Aldrich). Note: As it is a potent mutagen:
Personal protective equipment was used when handling EtBr. All EtBr
wastes were subsequently managed as hazardous waste.

3.1.7. Buffers used.
•

SOX Tris-Acetate EDTA buffer (TAE) stock electrophoresis buffer (g/1): 2M
Tris powder (Sigma-Aldrich) IM EDTA powder 2M Glacial Acetic Acid
adjusted to pH 7.8.

•

IX TAE running buffer with EtBr: 40ml SOX TAE in 1960ml H2O and
containing 20pl Ethidium Bromide.

•

IX TAE: As per TAE running buffer without EtBr.

3.1.8. Visualisation of extracted DNA.
•

Gel capture UV Transilluminator MiniBis Pro, (DNR Bio-Imaging
Systems).

3.1.9. Design of PCR primers.
•

BLASTn (http://www.ncbi.nlm.nih.gov/BLAST).

•

Ncbi genome (http://www.ncbi.nlm.nih.gov/sites/entrez?db=genome).

•

Ncbi entrez (http://www.ncbi.nlm.nih.gov/entrez/viewer).

•

Primer 3 software version 0.4.0.
(http://fokker.wi.mit.edu/primer3/input.htm).
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3.1.10. Genotypic analysis
•

dNTPs: (dATP, dCTP, dTTP, dGTP). 2.5 |il of each dNTP stock (lOOnM)
was added to 190|al of sterile water, to give a working stock of dNTPs at a
concentration of 1.25mM. (Cat no. 11969064001) Roche Diagnostics®

•

Taq Polymerase {Thermus aquaticus) with Magnesium Chloride (MgCb)
(25mM solution) and lOX PCR Buffer without MgCC [lOmM Tris-HCL
(pH 9.0), 50mM KCL, 0.1% Triton®X-100

•

Sterile lOOpl eppendorf tubes.

•

PCR primers: as outlined in table 3.2. section 3.2.7.3. All primers were
purchased from MWG-Biotech (Ebersberg, Germany).

•

DNA molecular weight marker Grade V: 8-587bp, 0.25pg/pl (Cat.
No.821705) Roche Diagnostics®

•

DNA molecular weight marker Grade III: 0.12-21.2kbp 025 pg/pl (Cat.
No.528552) Roche Diagnostics®

3.1.11 Spiking of samples.
•

Chlamydia transport swabs - RDI-microtest^'^ M4RT® swabs (Remel
Europe Ltd.)

3.1.12 Preparation of PCR products for Sequencing.
•

GenElute^*^ PCR Clean-Up kit (Sigma-Aldrich).
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3.2 Methods.

3.2.I.O. Collection of clinically derived organisms.
•

Each clinically derived Neisseria isolate had previously been identified by
the Microbiology Department at C.U.H. as either N. gonorrhoeae or N
meningitidis by routine methods ineluding API NH, Gram-stain and oxidase
test. Each isolate was first plated on to either chocolate agar eonsisting of
blood agar base no 2 (Oxoid Ireland, c/o Fannin Healthcare Dublin) or New
York City (NYC) agar, (lip Diagnostic services Galway) from beads to
ensure purity.

•

The non-neisseria isolates had also previously been identified by the
Microbiology Department at C.U.H. by routine methods including Gramstain, API 20E, DNase test, Lancefield’s grouping, production of black
pigment on KAA agar.

•

Each isolate was inoculated into vials containing threaded beads in a
cryopreservative fluid and frozen at -70°C until required for further use.

•

Eaeh isolate was also inoculated into vials containing 0.5ml of Brucella
broth and glyeerol and frozen at -KfC. The Brucella Broth and glycerol was
used to provide an alternative storage method for labile organisms such as
Neisseria gonorrhoeae and N. meningitidis.

3.2.1.1. Control organisms.
•

The three control organisms received from Microbiologies® Grenoble
France (ATCC3126, ATCC 23970, ATCC 29193), as KWIK-STIK TM

27

lyophilised reference stock cultures, were rehydrated according to the
manufacturer’s instructions.
•

Using the swab provided with each strain ,each isolate was plated onto
chocolate agar according to manufacturer’s instructions and were stored in
the same way as the patient isolates.

•

The two control organisms were received from the Health Protection
Agency, London, namely National Collection of Type Cultures (NCTC 3191
and 10294). Each of these isolates were reconstituted by adding Todd Hewitt
Broth, a loopful of each of these suspensions was plated onto a separate
chocolate agar plates and incubated at 37°C overnight. These organisms
were stored in the same way as the patient isolates.

3.2.2.O. Identification of organisms.
•

A Gram stain, oxidase test, catalase test and API NH was performed on each
of the Neisseria isolates before extraction of DNA was performed to confirm
their identity for this project.

•

The identities of the other non-neisseria isolates were also confirmed using
the appropriate tests outlined in section 3.2.1.0.

3.2.2.I. Gram stain.
•

A drop of sterile H2O was placed on a clean glass slide.

•

Using a sterile disposable loop one or two well isolated colonies were picked
and emulsified on the glass slide.

•

The slide was placed on a hot plate to fix the smear to the slide.

•

The slide was stained for 1 min with Crystal Violet.
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•

The slide was rinsed with tap water and stained for 1 min with Gram’s
Iodine.

•

The slide was again rinsed with tap water and differentiated using aeetone.

•

The slide was then counter stained with neutral red for 3 min.

•

The counter stain was washed off with tap water and the slide was blotted
dry using blotting paper.

•

The slide was placed on a hot plate to dry.

•

The slide was examined under oil immersion microscopy.

3.2.2.2. Oxidase Test.
•

Using a sterile disposable loop, 1 or 2 isolated colonies were picked from the
chocolate agar plate.

•

The loop was then rubbed onto a PYO oxidase test strip.

•

A purple colour appeared within a few seconds, according to the
manufacturer, if the organism was oxidase positive.

3.2.2.3. Catalase Test.
•

A loopful of H2O2 was placed on a clear glass slide.

•

A loopful of the organism was then placed into the H2O2 on the glass slide.

•

The appearance of effervescence denoted a positive result.

3.2.2.4. API NH.
•

Briefly, the incubation box was prepared according to the manufacturer’s
instructions.
The API strip was then placed in the incubation tray.
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•

An ampule of API NaCl 0.85% medium was opened according to the
manufacturer’s instructions. Using a swab, a few well-isolated colonies were
picked, and a suspension equivalent to the turbidity of a 4 Me Farland
standard was prepared in the API suspension medium.

•

The suspension was distributed into the cupules and the first seven tests
were covered with mineral oil to generate an anaerobic environment.

•

The strips were then incubated for 2 hrs @

in aerobic conditions.

•

A computerised identification matrix identified the organism by reference to
the Analytical Profile Index (API) of the Apiweb version 4.1 software
package:
(https://apiweb.biomerieux.com/servlet/Authenticate?action=prepareLoginf

3.2.2.5. API 20E.

•

This was prepared according to the manufacturer’s instructions in the same
way as the API NH except that a single isolated colony was used to make the
suspension.

•

The suspension was distributed into the cupules.

•

The cupules labelled, ADH, LDC, ODC, H2S and URE were covered with
mineral oil to generate an anaerobic environment.

•

The strip was incubated overnight @ 36°C in aerobic conditions.

•

Results were interpreted using Apiweb
(https://apiweb.biomerieux.com/servlet/Authenticate?action=prepareLogink

30

3.2.2.6. DNase Test.
•

A loopful of a suspension of the "Staphylococcus isolate was spotted onto
DNase agar and incubated @ 37°C overnight.

•

The plate was flooded with Hydrochloric acid (HCL).

•

The appearance of zone of clearing around the organism would have denoted
a S. aureus isolate while the absence of a zone around the organism would
have denoted a Coagulase negative Staphylococcus.

3.2.2.7. Lancefield’s grouping.
•

Lancefield’s grouping was performed on the Streptococcus isolates using
Streptex (D rapid agglutination test. This test was performed according to the
manufacturer’s instructions.

3.2.2.8. Production of black pigment on KAA agar.
•

The Enterococcus isolate was plated on to KAA agar and incubated @ 37°C
overnight.

•

The production of a black pigment on the agar denoted Enterococcus spp.

3.2.3.O. Extraction of DNA.
•

DNA was extracted from each of the isolates using Roche® High Pure
Template Preparation Kit.

3.2.3.I. Roche® High Pure Template Preparation Kit procedure for DNA
extraction.
•

The elution buffer was preheated to 70°C.
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•

A 200fxl volume of bacterial cells was acded to a nuclease-free 1.5ml
microcentrifuge tube.

•

The suspension was centrifuged for 5 min @ 3,000 x g.

•

The cell pellet was resuspended in 200pl PBS.

•

A 5pl volume of lysozyme (10 mg/ml in 10 mM Tris HCL, pH 8.0) was
added and the suspension was incubated for 15 min @ 37°C.

•

A 200pl volume of binding buffer and 40pl of reconstituted Proteinase K
(20mg/ml) were added and the suspension was mixed immediately and
incubated for 10 min @ 70°C.

•

A lOOpl volume of isopropanol was added and the tube was mixed well.

•

A high filter tube was inserted into a collection tube.

•

The liquid sample was transferred into the upper buffer reservoir of the filter
tube.

•

The entire filter tube assembly was insened into a standard table-top
centrifuge and centrifuged for 1 min @ 8,000 x g.

•

The filter tube was removed from the collection tube and the flowthrough
liquid and the collection tube were discarded.

•

The filter tube was combined with a new collection tube and 500pl of
inhibitor removal buffer was added to the upper reservoir of the filter tube.

•

This was centrifuged for 1 min @ 8,000 x g.

•

The filter tube was removed from the collection tube and the flowthrough
liquid and the collection tube were discarded.

•

A new collection tube was combined with the filter tube and 500pl of wash
buffer was added to the upper reservoir of the filter tube.

•

This was centrifuged for 1 min @ 8,000 x g.
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•

The filter tube was removed from the collection tube and the flowthrough
liquid and the collection tube were discarded.

•

A new collection tube was combined with the filter tube, and SOOql of wash
buffer was added to the upper reservoir of the filter tube.

•

This was centrifuged for 1 min @ 8,000 x g.

•

The flowthrough liquid was discarded and the entire High Pure assembly
was centrifuged for 10 s @ 17,000 x g.

•

The collection tube was discarded and the filter tube was inserted into a
clean sterile 1.5ml centrifuge tube and 200pl of elution buffer was added to
the upper reservoir of the filter tube.

•

This was centrifuged for 1 min @ 8,000 x g leaving the eluted DNA retained
in the microcentrifuge tube.

3.23.2. Extraction of DNA in spiked samples.
•

Four 1.5ml eppendorf tubes were labelled 1 to 4.

•

A 500pl volume of transport medium from Remel ® Chlamydia transport
swabs was placed in tubes 1 and 2.

•

A 500pl volume of sterile H2O was placed into tubes 3 and 4.

•

Using a sterile cotton-tipped applicator swab, one isolated colony of an
overnight culture of N. gonorrhoeae ATCC 3126 was picked from chocolate
agar and emulsified into the transport medium in tube 1.

•

This was repeated for tube 3.

•

Again using a cotton tip swab 5 colonies were picked from chocolate agar and
emulsified into the transport medium in tube 2.

•

This was repeated for tube 4.
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•

The DNA was extracted from each of the spiked samples using an ‘in-house’
(Microbiology CUH), boiling method.

•

All the tubes were heated to 100°C for 10 min.

•

The tubes were centrifuged @ 10,000rpm for Imin.

•

The supernatants (which contained the DNA) were transferred into fresh
eppendorf tubes.

3.2.4. Qualitative analysis of extracted DNA.
•

The quantity of DNA extracted for each isolate was measured using a
nanodrop 1000 spectrophotometer.

•

The nanodrop 1000 was first cleaned by placing 1 pi of sterile H2O on its
pedestal and by following the instructions on the screen.

•

The instrument was then set to Zero using the elution buffer from the
Roche® High Pure Template Preparation Kit.

•

The isolate number was entered in the space labelled sample ID on the
screen.

•

The DNA sample to be measured was flicked gently to homogenise the
DNA within the suspension.

•

A volume of 1 pi of the DNA was placed on the pedestal of the nanodrop and
measure was clicked on the screen.

•

The nanodrop measured the concentration of DNA in ng/pl.

3.2.5. Qualitative analysis of extracted DNA.
•

Each sample was prepared by adding 2pl of loading dye and lOpl of
extracted DNA to an eppendorf tube.
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•

One tube containing 2gl of loading dye, 8|al of H2O, and 2|il of molecular
weight marker III was used to create a DNA ladder.

•

Depending on the number of lanes required, a large or small 1% agarose gel
was prepared as follows:
o Large 1% agarose gel: Ig of purified agarose powder was added to
100ml of IX TAE buffer and microwaved for 1 min at 750°C. Once
the gel had cooled to < 50°C a 1 pi volume of EtBr was added and the
solution was homogenised gently.
o

Small agarose gel: 0.4g of purified agarose powder was added to 40ml
of IX TAE buffer and microwaved for 1 min at 750°C. Once the gel
had cooled to < 50®C a 0.5pl volume of EtBr was added and the
solution was homogenised gently.

•

The gel was poured into a pre-prepared electrophoresis tank containing a
sample well comb, and was allowed to set.

•

Following the removal ot the sample well comb, a volume of IX TAE
running buffer was poured over the gel sufficient to cover the surface of the
hardened gel.

•

All the samples were loaded into separate wells.

•

A current of 80 volts (V) was run through a small gel and a current of 100V
was run through a large gel.

•

The DNA bands were then visualised using a Gel capture UV
Transilluminator MiniBis Pro.
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3.2.6.O. Design of PCR primers.
•

PubMed was first searched for articles, which referred to genes, which had
been used by other authors as targets for PCR assays. These articles were
also assessed for the specificity and sensitivity of the targets reviewed.

•

References to PorA, CarA and the opa genes were found (Whiley et al,
2006; Smith, 2005; Mayta et al, 2006).

•

The literature was then searched for references to housekeeping
genes.(Viscidi & Demma, 2003, Perez-Losada et al, 2005, Potter et al,
2007).

•

Using these papers a list of candidate genes was drawn up.

•

Using entrez gene each of the candidate genes were located and their locus
tag (position in the genome) was noted.
(http://www.ncbi.nlm.nih.izov/sites/entrez?db=tJene).

•

Using entrez viewer, which has a full list of the genes of N. gonorrhoeae
strain FA109, which has been completely sequenced, the locus tag for each of
the genes was found along with the nucleotide sequence for each gene.
(http://www.ncbi.nlm.nih.^ov/entrez/viewer.fcgi?db=nuccore&id=59800473)

•

The nucleotide sequence was then copied and pasted into BLASTn and a
search for matches was performed.

•

An extensive analysis of areas that are common to all N. gonorrhoeae strain
sequences present in GenBank and EMBL databases and different from
other species was conducted to see if they were suitable for use as PCR
primers.

•

When all of the candidate genes were analysed in this way a list comprising
of 14 potential candidate genes was drawn up.
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•

The regions of these genes that appeared unique to N. gonorrhoeae strains
were entered into the Primer 3 programme to look for potential primers.

•

The potential primers identified by Primer 3 were copied and pasted into
BLASTn to ensure that they were both unique to N. gonorrhoeae and
present in all known N. gonorrhoeae strains.

•

Three primer pairs were chosen based on product size and annealing
temperature for three genes, namely PorA, Pgil and Pgm.

•

The primers were named as follows:
o

Por A F.

o

Por A R.

o

Pgi 1 F.

o

Pgi 1 R.

o

Pgm F.

o

Pgm R.

3.2.6.I. Design of internal control primers.
•

Vibrio cholerae was chosen as an internal control as this is an unlikely coinfective organism in genital species. No reference to co-carriage of N.
gonorrhoeae and V. cholerae was found in the published literature.

•

The selection of internal control primers was made on the basis of a
literature search for primers that had already been used, and which were
unique to V. cholerae. A final selection was made based on a primer pair
which amplified a suitably-sized amplicon for inclusion in the N.
gonorrhoeae PCR assay and which had a comparable annealing temperature
to the primers already in use in this study. Note the guanine and cytosine
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content and annealing temperatures of all of the primers were calculated
using the Primer 3 programme.
•

The internal control primers were named, IC F and IC R.

•

All of the primers were selected so that their amplicons could be run on a
conventional agarose gel and so that they could be seen clearly as individual
bands within the multiplex assay. The primers were also selected so that
their amplicons would be of a suitable size for sequencing without the need
to design internal primers when sequencing.

3.2.7.0. Genotypic analysis.

3.2.7.1. Preparation of primers.
•

All of the primers were purchased as lyophilised preparations and were
reconstituted to a stock solution of lOOpmol/pl by adding sterile distilled
H2O to the total volume recommended by the manufacturer.

•

Each of the primers was prepared to a final working concentration of
25pmol/pl by adding 25 pi of the lOOpmol/pl concentration solution to 75 pi
of sterile H2O.

3.2.7.2. Preparation of DNA.
•

A final volume of DNA was prepared from the extracted DNA solutions
using the following formula:
VI = CF

Cl
CF
VI
VF

=
=
=
=

X
Cl
initial concentration.
final concentration.
initial volume.
final volume.

VF
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3.2.7.3. Por A uniplex assay.
•

The conditions and primer sequences used in the PorA uniplex assay are
summarised in table 3.1. and table 3.2. A primer annealing temperature of
52°C was initially used to ensure annealing of all the primers would occur.
Once it was established that the PCR reaction was working effectively this
was increased to 58°C, to increase the stringency of annealing and to
reduce the possibility of non-specific products being generated. The
temperature of 58°C was chosen as it was just below the annealing
temperature of the porA forward primer, which had the lowest annealing
temperature of the primers used.

•

A master mix was made up including dNTPs at a concentration of 0.8
mmol/1, MgCbat a concentration of 2.5 mmol, and primers at a
concentration of 0.05 pmol/pl.

•

PCR was run on control isolate DNA, (isolate CUH 37) ATCC3126 as
outlined in table 3.1.

•

The PCR products were visualised on a 1.5% agarose gel.

Table 3.1. Amplification programme for PCR assay.
Number of cycles

Temperature

Time

1

Initial Denaturation

95‘'C

5 min

35

Denaturation

95^C

30 s

Primer Annealing

52/58‘^C

30 s

Extension

72 °C

30 s

Final Extension

72 ^C

5 min

1
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3.2.7.4, Multiplex PCR assay.
•

A multiplex PCR assay using primers for the PorA gene, Pgil gene and
the Pgm gene was performed using the conditions and primer sequences
outlined in tables 3.1. and 3.2.

Table 3.2. Primer sequences for amplification of the Por A gene, Pgil gene, the Pgm gene
and the internal control (1C) gene.
Primer sequence

Reference

Por A F

CGGCAGCATTCAATTTGTT

This study.

PorA R

TCAATGGATCGGTATCACTCG

This study.

Pgil F

AAACACCTTCACGACTTACCG

This study.

Pgil R

CCAACTCGAACAGTAGGGACA

This study.

Pgm F

CTCCGCCGTGTTCTITAATC

This study.

Pgm R

AAACTCAAACGCCCGATAAAC

This study.

IGF

CTCCGCTCCTGTATTTGCTC

This study.

IC R

AAGCGTTGAGGAACCAGCTA

This study.

3.2.8.0 Optimisation of multiplex PCR assay.

3.2.8.I. Optimisation of MgCb concentration.
•

Four concentrations namely, 0.5mmol, 1 .Ommol, 1.5mmol, and 2.0mmol
of MgCl2 were prepared.

•

Four master mixes were prepared using different MgCf concentrations.

•

A multiplex PCR assay was performed using each of the master mixes,
and N. gonorrhoeae ATCC 3126 and their products were visualised.
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3.2.8.2. Optimisation of MgCh and dNTP concentration.
•

In order to determine the optimal concentrations of MgCb and dNTPs in
the assay, multiplex PCR assays were performed (using the following
concentrations):
o The MgCl2 concentrations used were 1.5 mmol, 2.0 mmol and 2.5
mmol.
o The dNTP concentrations were 0.6mmol/l, 0.7 mmol/1 and
0.8mmol/l.

3.2.8.3. PCR using internal control primers.
•

Two PCR assays were performed and their products were visualised. The
first was a uniplex assay using the primers for the internal control only and
the second assay was a multiplex PCR, using primers for the internal
control, the ParA gene, Pgil gene and the Pgm gene.

•

In order to determine the effect of the internal control primers with each of
the other primers, duplex assays were run with the internal control primers
and each of the other primer pairs individually. A multiplex assay using all
the primers as outlined above was also repeated.

3.2.8.4. PCR assay using an annealing temperature of 58"C.
•

A multiplex PCR reaction including primers for porA, pgil and the
internal control was performed on DNA from N. gonorrhoeae ATCC
3126.
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•

PCR was performed on this sample as outlined in table 1 using the higher
annealing temperature of 58°C and the PCR products were visualised.

3.2.9. Testing of clinical and control isolates.
•

A multiplex PCR assay using the primers for the PorA gene, the Pgil gene
and the internal control was performed on each of the clinical and control
isolates.

•

This PCR assay used the amplification programme outlined in table 3.1. (using
the higher annealing temperature of 58°C).

3.2.10. Determination of the limit of detection of N. gonorrhoeae DNA.
•

The control N. gonorrhoeae DNA ATCC 3126 was serially diluted to give the
following concentrations (ng/pl): 160, 80, 40, 20, 10, 5, 2.5, 1.25, 0.625,
0.3125 and 0.15625.

•

The multiplex PCR assay was performed using each of these concentrations of
DNA to determine the lowest concentration of DNA detectable using this
assay.

3.2.11. Detection of DNA in spiked samples.
•

The multiplex PCR assay was run on each of the DNA extracts from the four
spiked samples.

3.2.12.0. Sequencing of the PCR products of one clinical N. gonorrhoeae isolate
and those of the internal control.
•

Isolate CUH 29 was randomly chosen for sequencing of its PCR products.
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•

Four PCR assays were prepared with:
o Isolate CUH 29 using pgrn primers,
o Isolate CUH 29 using porA primers,
o Isolate CUH 29 using pgil primers,
o

•

V. cholerae using internal primers.

PCR was performed for each assay as outlined in table 3.1. using an annealing
temperature of 58°C.

•

Each of the products of the PCR reactions was prepared for sequencing using
the Sigma GenElute™ PCR Clean-Up kit.

3.2.12.1. Sigma GenElute^''^’ PCR Clean-Up kit procedure.

•

This kit was used according to the manufacturer’s instructions. Briefly a
GenElute miniprep binding column was inserted into a collection tube.

•

A volume of 0.5ml of column preparation solution was added to each
miniprep column and these were centrifuged at 12,000 x g for 30 s.

•

The eluate was discarded.

•

Five volumes of binding solution to 1 volume of PCR reaction were added to
the miniprep column.

•

The column was then centrifuged at maximum speed for 1 min.

•

The eluate was discarded.

•

A volume of 0.5ml of diluted wash solution was added to the column and
centrifuged at maximum speed for 1 min.

•

The eluate was discarded.

•

The column was centrifuged at maximum speed for 2 min to remove excess
ethanol.
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•

The eluate and the collection tube were discarded and the column was
combined with a fresh collection tube.

•

A volume of 50|il of sterile H2O was applied to the centre of each column and
then incubated at room temperature for 1 min,

•

The column was centrifuged at maximum speed for 1 min to elute the DNA
into the collection tube.

3.2.12.2. Preparation of PCR products for sequencing according to the
instructions of MWG-Biotech.
•

A minimum volume of 15pl of each of the purified PCR products were added
to two pre labelled 1.5ml eppendorf tubes to allow for forward and reverse
sequencing.

•

A minimum volume of 15pl of each of the primers at a concentration of
2pmol/pl were added to 1.5ml eppendorf tubes.

•

Each of these was sent for sequencing to:
Eurofms MWG Operon in Germany.

•

A forward and reverse sequence was obtained for each of the PCR products.

•

The forward and reverse sequences for each gene were aligned using the
alignment tool in NCBI BLAST,
(http://blast.ncbi.nlm.nih.gov/bl2seq/wblast2.cgi).
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4.0. Results.
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4.0 Results.
4.1. Identification of organisms.
•

Each isolate used in this study was identified as described in section 3.2.2.

•

The identification of each isolate along with their Gram result, API profile,
oxidase and catalase result is listed in table 7.1. in the appendix section.

4.2 Extraction of DNA.
•

The DNA of each isolate was extracted, as outlined in section 3.2.3, and
analysed as outlined in sections 3.2.4. and 3.2.5.

•

The concentration of DNA extracted from each sample was determined using
the nanodrop 1000 spectrophotometer. See appendix figure 7.1.

•

The extraction was repeated for any isolate that either had a concentration of
less than 50ng/pl or was not clearly visible when run in a 1% agarose gel.

•

The quality of DNA extracted from each sample was determined by running it
on a 1% agarose gel. See Appendix figure 7.2.

4.3 Design of PCR primers.
•

As described in section 3.2.6 a list of genes which could possibly be used as
targets for a PCR assay to detect N. gonorrhoeae was compiled by searching
PubMed for genes which had been used in previously-published assays, and
for genes which had been described in publications as housekeeping genes of
N. gonorrhoeae, these genes are shown in table 4.1.
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Table 4.1. Putitive target genes for use in the detection of N. gonorrhoeae by
multiplex PCR.
Name of
gene

Function

Result of further
analysis

AbcZ

H

E

AdhC
Adk

H
H

E
E

AroE

H

E

CarA
CppB

PD
PD

E
E

FumC

H

E

Gdh

H

E

GinA

H

E

Gnd

H

E

Gpdh
GpdhC
Opa
PdhC

H
H
PD
H

E
E
E
E

pgii
Pgi2
Pgm

H
H
H

1
E
I*

PilA

H

E

Pip
PorA
Ppk

H
PD
H

E
I
E

PyrD

H

E

SerC

H

E

Reference

(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Potter et al., 2007)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Mayta et al., 2006)
(Farrell, 1999, Whiley et al.,
2002)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Viscidi & Demma, 2003)
(Viscidi & Demma, 2003)
(Geraats-Peters et al., 2005)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Viscidi & Demma, 2003)
(Viscidi & Demma, 2003)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Viscidi & Demma, 2003)
(Hjelmevoll et al., 2006)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)
(Perez-Losada et al., 2005,
Viscidi & Demma, 2003)

Note: H = Housekeeping gene. PD == Previously described as being used in a PCR
assay to detect N. gonorrhoeae. E = Excluded from final assay. I = Incorporated as a
target in the multiplex assay designed in this study. * = included initially but later
excluded on the basis of size.
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•

The position (locus tag) in the genome and the nucleotide sequences of these
genes were found by the method described in section 3.2.6. and are
represented in figure 4.1 for the pgm gene.

•

Using the locus tag, the nucleotide sequence was located as described in
section 3.2.6.

•

A search for matches for the nucleotide sequences for each gene was
performed in BLASTn and an analysis of areas of each gene common to all N.
gonorrhoeae strain sequences was performed as described in section 3.2.6. and
shown in figure 4.2 for the pgm gene. See figures 7.4 and 7.8, in the appendix
section for a representation of the BLASTn analysis of the entire pgil and
parA genes respectively.

•

Suitable primers were selected with the aid of the primer 3 programme
(http://fokker.wi.mit.edu/primer3/input.htm).

•

These primers were entered in BLASTn to ensure that they were unique to N.
gonorrhoeae, and were present in all submitted N. gonorrhoeae sequences for
that gene.

•

Figure 4.3 (a) represents the primers selected for the pgm gene with the aid of
the primer 3 programme. Figure 4.3 (a) also details the annealing temperature
(Tm), the guanine and cytosine (GC) content, the position of the primers in the
gene and their product sizes.

•

Figures 7.5 and 7.9 in the appendix section show representations of the primer
pairs selected with the aid of the primer 3 programme for pgil and porA genes
respectively.
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Figure 4.1. Result of Entrez investigation for the locus tag
NGO0375 of the pgm gene.
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Figure 4.2. (a). BLASTn search of entire pgm gene. There are five
linked sequences for this gene in GenBank.
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Figure 4.2. (b). BLASTn search of a small section of the pgm gene (this part
of the gene matches all known sequences for this gene). Note this part of the
gene was chosen by looking at the BLASTn result of the entire gene and
choosing an area that appeared conserved between all N. gonorrhoeae
sequences listed.
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•

Figure 4.3 (b) and (c) show the BLASTn search of the pgm forward and
reverse primers. Each of these primers match perfectly each of the known
sequences of the pgm gene in N. gonorrhoeae. In the case of the reverse
primer the closest matching N. meningitidis strain has a mismatch of each of
the first five bases of the primer. This would make it unlikely that this primer
would amplify such N. meningitidis strains.

•

Figures 7.6 and 7.7 in the appendix section illustrate the BLASTn searches of
the pgil forward and reverse primers respectively. The sequences of both of
these primers matched perfectly to each of the known sequences of the pgil
gene in N. gonorrhoeae.

•

Figures 7.10 and 7.11 in the appendix section illustrate the BLASTn searches
of the porA forward and reverse primers respectively. The sequences of both
of these primers matched perfectly to each of the known sequences of the porA
gene in N. gonorrhoeae.

•

The final primers chosen as the most suitable for use in the multiplex PCR
assay, along with the primers for the internal control gene are listed in section
3.2.7, table 3.2.
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56

4.4. Genotypic analysis.
•

A multiplex of the three primer pairs for the PorA, Pgil and Pgm genes was
performed using the control N. gonorrhoeae strain (ATCC 3126) as described
in section 3.2.7.4. and shown below in figure 4.4.

Pgm

434 bp

PorA
Pgil

Figure 4.4. Multiplex PCR of N. gonorrhoeae (ATCC 3126). Note:
Lane 1 = negative control. Lane 2 = Test (ATCC3126). Lane 3, M =
Grade V molecular weight marker.
Each of the three target genes Pgm, PorA, and Pgil are clearly amplified
showing the anticipated product sizes of 397, 260 and 196bp.

4.4.1. Optimisation of multiplex assay.
•

The MgCC and dNTP concentrations were optimised as described in section
3.2.8.2.

•

It was found that a MgCC concentration of 2.5 mmol and a dNTP
concentration of 6mmol/l were optimum for this assay, as demonstrated by the
presence of stronger bands when these concentrations were used compared to
any other concentration as shown in figure 4.5.
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Figure 4.5. Multiplex assay using various concentrations of MgCl2 and dNTP
ranging from 1.5 to 2.5mmol and from 0.6 to 0.8mmol/l respectively. Note: Lane 1,
[MgCy = 2.0mmol, [dNTP] = 6.0mmol/l. Lane 2, [MgCb] = 2.0mmol, [dNTP] =
7.0mmol/l. Lane 3, [MgC^] = 2.5mmol, [dNTP] = 6.0mml/l. Lane 4, [MgCb] =
2.5mmol, [dNTP] = 7.0mmol/l. Lane 5, [MgCh] =1.5mmol, [dNTP] =8.0mmol/l.
Lane 6, [MgCb] = 2.0mmol, [dNTP] ^8.0mmol/l. Lane 7, [MgC^] = 2.5mmol,
[dNTP] = 8.0 mmol/1. M = grade V molecular weight marker.
•

The effect of inclusion of internal control primers on the multiplex assay was
evaluated as described in section 3.2.8.3. and shown in figure 4.6. It was
found that the internal control band interfered with the pgm band, as both
products were too close in size (423bp and 397bp respectively). It was
therefore decided that the pgm primers should be excluded from the assay, i.e.
leaving two N. gonorrhoeae specific primer pairs and an internal control.

434 bp
267 bp
192 bp

Figure 4.6. Effect of inclusion of internal control primers on each individual primer
pair used in the multiplex assay. Note: Lane 1, internal control + pgm, lane 2 negative
control, lane 3 internal control + porA, lane 4 negative control, lane 5, internal control
+ pgil, lane 6 negative control, lane 7, internal control,and porA, lane 8
negative control, lane 9 grade V molecular weight marker.
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4.4.2. Testing of clinical and control isolates.
•

The DNA from each isolate listed in table 7.1 in the appendix along with the
DNA from the group A Streptococcus and group B Streptococcus were tested
using the multiplex PCR assay as described in section 3.2.9.

•

A selection of results of N. gonorrhoeae and non-A. gonorrhoeae isolates is
shown in figure 4.7 below.

•

The results of this assay for the entire collection are shown in figures 7.12,
7.13, 7.14, 7.15 and 7.16 in the appendix section.

•

Each of the N. gonorrhoeae isolates were positive for both porA and pgil.

•

All of the other isolates were negative for porA and pgil but were positive for
the internal control, ensuring that all negative test results were accompanied
by a product to demonstrate the efficacy of each PCR test within the run
(figure 4.7).

12

34

567

89

10

11

M

434 bp
237bp
192 bp
Figure 4.7. Multiplex PCR of isolates 34-44 (see table 1). Only the internal control
amplified in the non-gonococcal isolates. The internal control,and pgil all
amplified in the gonococcal isolates. Lane 1, N. meningitidis (internal control), lane 2,
N.cinerea (internal control only), lane 3, N.flavescens (internal control only), lane 4, N
gonorrhoeae, (internal control,/7oryt and pgil), lane 5, Ngonorrhoeae, (internal control, por/t
and pgil), lane 6, Ngonorrhoeae, (internal control,
and pgil), lane 7, Ngonorrhoeae,
(internal control, poryt and pgil), lane 8, Ngonorrhoeae, (internal con\.vo\, porA and pgil),
lane 9, N. sicca, (internal control only) lane 10, N. lactarnica, (internal control only) lane 11,
Ngonorrhoeae, internal control,and pgil), lane 12, grade V molecular weight marker.
(See appendix for other isolates).
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•

The sensitivity and specificity for this assay were 100%.

•

The sensitivity was calculated using the following formula:
Sensitivity = The number of N. sonorrhoeae isolates detected.
The total number of N. gonorrhoeae isolates.

•

The specificity was calculated using the following formula:
Specificity == The total number of correctly identified isolates.
The total number of isolates.

4.4.3. Determination of the limit of deteetion of N. gonorrhoeae DNA.
•

The limit of detection was determined as described in section 3.2.10.

•

The lowest concentration of DNA detected by this assay was 1.25ng/pl of
DNA in the assay, which is equal to 5ng of DNA in the assay since 4pl of
DNA was used in each assay. This was the lowest concentration of DNA
which produced visible bands for both the parA and pgil targets (figure 4.8).

Figure 4.8 (a). Serial dilutions of N. gonorrhoeae (ATCC 3126) DNA were used to
determine the limit of detection of the multiplex PCR assay. This gel shows the results of
the multiplex PCR run on various dilutions of DNA as follows: lane 1, 1.25ng/pl. Lane 2,
2.5 ng/pl. Lane 3, 5ng/pl. Lane 4, lOng/pl. Lane 5, 20ng/pl. Lane 6, 40ng/pl. Lane?,
80ng/pl. Lane 8, 160 ng/pl. Lane 9, negative control Lane 10, grade V molecular weight
marker. Note: 4pl of DNA was used for each PCR assay and the total volume in each PCR
assay was 50pl. Therefore for the reaction shown in lane one, for example, where a DNA
concentration of 1.25ng/pl was used, a total of 5 ng of DNA was placed in this assay.
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434 bp

237 bp

192 bp
Figure 4.8. (b). This gel shows the results of the multiplex PCR run on
various dilutions of DNA as follows: lanel, negative control. Lane 2,
0.156 ng/pl. Lane 3, 0.312 ng/pl. Lane 4, 0.625 ng/pl. Lane 5,
1.25ng/pl. Lane 6, grade V molecular weight marker.

4.4.4. Detection of N. gonorrhoeae DNA in spiked samples.
•

Four samples were spiked with N. gonorrhoeae as described in section 3.2.11.
and shown in figure 4.9.

•

Each of the four samples produced visible bands for porA and pgil in addition
to the internal control.

•

The sample of transport buffer spiked with a single colony produced weak
bands, which are visible in figure 4.9, it is clear however that the bands are
present.
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Figure 4.9. Detection of DNA in samples that were spiked with N. gonorrhoeae. Lane
1, negative control. Lane 2, five colonies in 500pl of H2O. Lane 3, one colony in
500pl of H2O. Lane 4, five colonies in transport buffer. Lane 5, one colony in
transport buffer. Lane M, grade V molecular weight marker.

4.4.5. Sequencing of PCR products.
•

The sequencing results of the PCR products of the pgil, parA and pgm genes
of isolate CUH 29 {N. gonorrhoeae) and the internal control are listed below
in table 4.1.

•

The forward and reverse sequences for each gene are listed in table 4.1.

•

The chromatographs to accompany each of these sequences are shown in
figures 7.17, 7.18, 7.19, 7.20, 7.21, 7.22, 7.23 and 7.24 in the appendix
section.

•

The forward and reverse sequences for each gene aligned using using the
alignment tool in NCBI BLAST are shown in figures 4.10, 4.11, 4.12 and 4.13
below.
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Table 4.3. Sequences of the PCR products of isolate CUH 29 and internal
control. See appendix for alignments and chromatographs.
Gene

Length
(bp)

Sequence

PorA

222

TCGCCTATACX]CCTXXTA(JTTrcACGCT03AAAGTAATCAGATCAAA(XAGTT^
(^GCFGTTiGTCGGCAAGCCGGGGTGGGATGTGTArrATGCCGGTCrGAATrACAAA
AATGGOGGC11111CGGAAATTATGCOCITAAATATGCGAAACACGCCAATGAGG
GGCATGATGCTITC Hill GTTCTIGCTraXAGAGCGAGTGATACCGATCCATTG
AA

224

GAGCATGATGOCraGATKX}(XITGTTTCXK:ATATTTAAGGGCATAATTTGCGAA
AAA(30CXKrATTTTTCTAATrcAGA00GGCATAATACACATC0GACG00GGCTTG
(3CGACAACAGCCXX}AACK}GTTTGATCTGATTACTTTGCAG(7GTGAAAGTA(3CAG
(3CGTATAGG(XK3ACTTGaX3TTTTGACTXXK}AACAAATTX3AATGCTX3CCGAA(3CA
ACTAG

169

ATGTGGACACTTTGA(XJACAGCAAAACATTGCATATGCGCGAAATGTTGGA(XA
AGAaXXK:AGaKXjCGGAACGCrACrcGCnXAAGTCXX3a3GACTGA(XCTGGA
CTACrcCAAAAACaXATCAAaiACjGAAAa^ATGTC(XTACrcTTO3AGTTCGAA
TTGGTFC

156

GlTTTGGAGTAGT(XAGCGTCAGTCra70GA(mXX:AGCCAGTAGCGTrGCGCCC
GCTXXXX]GTITrGaGGAACAT[TGGCXXATATGCAATGTTTFGCrGTCX33GAAAG
TGGTTCCACAATTnX3A<XAGGCCGGTAAGTCGTGAAGGTGTTATG

356

ACATCX}AAATGACTTTIX]CG<XGGGATTGCGGriGAAAACGTCTTGGGCGAACAG
CATCAGTrGGCGGTtXGGATAAATAATGTrocrGTCTTTGGTAACCACXJCCCAAG
<7(3GTlXiGCATCGaXTCAAAC(3(XAAGCCGATTTCGGCAlGGCCGTTTITlCA(3CG
CGGCAATCAAATCTTiGCAGGTrrrcCCKiTTTGGAAGGATCA(3GGTGGTGATTAGG
GAAATTG(XX3T(XA(7nxriCAGAAAAGTTCX3GTC ACTT10GTTC3CCCAAACCTTK3T
AGAGTTTGCC(3GCAAA(XiC(30:GCCCA(XCCGTTGCCCGCX3TCGAT(3GCGATGTT
TATCX3GG03CTTGAGTTTAAAGCrFG

353

GaiCGCA(j(3GCGTGGGCGG(3GCXiTTTGCCXXK:AAACFCrACAAAGGlTTGGGCA
ACX3AAGTGA(XGAA(JITmTOjGAAGTGGACGGCAATTT0CCrAATCACCACCC
TGATlXTnXAAACO(3GAAAA(XTGCAAGATlTGATrGCCGCGCFGAAAAACGGC
GATGCCGAAAT(XKXTTXX}CGTnX3ACGGa}ATGCCX}A(XGCITGGGCGTGGlTA
a:AAAGACGGCAACATTATTTAT(XCGACCGCCAACTGATGCrGTTCGCCCAAGA
CGTrTTGAA(70GCAAT0a3GGCGCGAAAGTCArTTTlCGATGTCAAATCCACACGC
CTGCTTG(3CCCGTGGATTAAAGAAA

306

CAATAGTACTTTX]GTCAAGCrAATKX}ACTTrOCXJIXrATATGTrcGTGC(3GGTT^
GAATTACA(XACnTCTTTGATGAAA(XTTTAATGGTACGGGTACrAAT(3CTGGA
™AGTGAriTAAAA(JTTGA(XiACrcATGGGGA(7nGCKKTAACGTrGGCTTTG
ATTATATGCTCAATGATAGCrcGTTXXTGAACXKTrCTGTGTGGTATGCCAATATr
GAAACAACGGCAACCTACAAAGCAGGTGCAGATGCCAAATGCACGGATGTTGAA
ATCAATtXrrGGGTATTTATGTCXXKXJGGTG

370

TTXX]CATCKrACXnX3CTTTGTAGGTTG(XX3TrcTm:AATATTGGCATA(XACAC
AGAAGCGTTGAGGAA(XAGCTATCATrGA(3CATATAATCAAAGCCAACGTrAGC
AGCAAGTCXXrATGAGTGGTCAAGTnTAAATCACTGAATOCAGCATTAGrACCC
GTAOCATrAAAGCrniCATCAAAGAAAGTGGTGTAATTCAAA(XC(3CA(XAACAT
ATGGAOGGAAAGTCGAATTAGCTTCACCAAAGTAGTATTGGAOCATAAAGGTAG
GTGGCAAAT(JTTTTGTTrcACCAATATCACCAAGGCrAOCTAACrcACCACCAGA
(3GTAGAAATCTTATGTGAAAATGGCGTAGCA(3CGA(3GCATrc

(Forward
sequence)

PorA
(Reverse
sequence)

Pgil
(Forward
sequence)

Pgil
(Reverse
sequence)

Pgm
(Forward
sequence)

Pgm
(Reverse
sequence

Internal
control

ompw
(Forward
sequence)

Internal
control

ompw
(Reverse
sequence)
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Figure 4.10. Alignment ofpgiJ forward and reverse sequences from
isolate CUH 29.
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Figure 4.11. Alignment ofporA forward and reverse sequences
from isolate CUH 29.

65

a tt 0

(A H U

e)|

H rt 0

m H

s il

C (A 01

(A) tr

a oH

Hurt

|0
i|:
'

i

lEi.
: T3
: Q^
: O
;

i

i

#
ll^
j
\

i

i

'• **M

i

i

tf
□

; ^!
in
Figure 4.12. Alignment of pgm forward and reverse sequences
from isolate CUH 29.
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Figure 4.13. Alignment of ompfV gene forward and reverse
sequences from the K cholerae internal control strain.
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5.0. Discussion.
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5.0 Discussion.
N. gonorrhoeae is recognised as an important pathogen, which commonly
causes a sexually transmitted infection in individuals in both industrialised and
developing nations (W.H.O., 2001). In recent years there has been a steady increase in
the number of cases in Ireland and this trend has also been minored in other countries
(HSPC, 2006). This infection often occurs asymptomatically with such individuals
acting as reservoirs of further infection. Although infection with N. gonorrhoeae is
easily treatable with antibiotics, if undetected it can have devastating consequences
for the patient such as infertility, PID, and increased risk of ectopic pregnancy (Ghosh
et al, 2004).
It is widely accepted that although culture is considered the ‘gold standard’
for the diagnosis of N. gonorrhoeae it is not ideal for routine testing of clinical
samples (Tapsall, 2001). The specificity of culture can be 100% if followed by the
correct confirmatory tests. The sensitivity of culture can however be very low,
particularly when testing pharyngeal or rectal specimens, or if there is a delay in the
transport of the specimen to the laboratory (Young et al, 2003; Van Dyck et al, 2001).
As a result many non-culture methods have been developed. However these too have
demonstrated problems with regard to specificity and sensitivity. Many of the
commercial systems which have been developed, such as LCR, BDProbe Tec and
Amplicor assays have been shown to produce false positive results (Palmer et al,
2003; Tabriz! et al, 2004). These problems are generally a result of the instability of
the N. gonorrhoeae genome and it’s propensity for genetic exchange with commensal
Neisseria spp. (Goire et al, 2008). As a result, laboratories that use commercial or ‘in
house’ assays generally confirm any positive results using either a second NAAT
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assay targeting another gene, or by confirmation of the diagnosis by another
technique.
This study aimed to address any potential lack of specificity associated with
molecular techniques, by including two N. gonorrhoeae gene targets in a multiplex
assay along with an internal control. It was hoped that by including more than one
target gene, the potential for sequence related false-positive and false-negative results
might be reduced, as it would be unlikely that a strain of N. gonorrhoeae would lose
both genes simultaneously or that a non-gonococcal strain would acquire both genes
simultaneously. There is a significant distance between the two target genes used in
this study as they are positioned 216 Kb pairs apart. The inclusion of a second target
also provided simultaneous confirmation of a positive result.
An internal control target was included as the specimens which are tested for
N. gonorrhoeae often contain inhibitory substances that interfere with the PCR
reaction (Whiley et al, 2006b). An internal control is a non-target DNA sequence in
the same sample reaction tube, which is co-amplified simultaneously along with the
target sequence (Hoorfar et al, 2003). The internal control serves to indicate whether
amplification has occurred for each sample. Unless inhibition of PCR (by inhibiting
substances) can be detected, a false negative result can occur. The reporting of such
false negative results could produce serious long-term effects for the patient as
discussed in section 1.2, and may also result in the further spread of infection. The
inclusion of an internal control validates a negative result as it shows that the PCR
reaction is working in an individual sample, and the absence of amplification of the
internal control would flag any problems with the PCR assay. The internal control is
therefore considered to be a very important component of this assay. The importance
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of internal controls in NAAT assays is highlighted by calls to make such internal
controls in NAAT assays mandatory (Hoorfar et al, 2003).
The internal control target used in this assay was the outer membrane protein
OmpW of V. cholerae. A gene from V. cholerae was chosen, as it would be extremely
unlikely that a patient suffering from a N. gonorrhoeae infection would be
simultaneously carrying V. cholerae asymptomatically, which might in turn interfere
with the detection of N. gonorrhoeae due to a potentially overwhelming concentration
of a non-gonococcal target. There is no reference to simultaneous carriage or infection
with N. gonorrhoeae and V. cholerae in the published literature to date anywhere in
the world. A PCR assay targeting the ompW gene was found in the literature (Nandi et
al, 2000), so this gene was chosen as a putative internal control. The published
primers when entered into the Primer 3 programme were found however, to have a
high degree of self-complementarity and so would be prone to forming secondary
structures which would interfere with their annealing to the template. One of the
primers was also found to have high 3’ stability, as its 3’ end was very rich in guanine
and cytosine bases. This would interfere with the dissociation of the primer from the
template strand during the denaturation step of the PCR reaction. It was therefore
necessary to design two new primers for this gene for use in this study. These primers
were designed to ensure that they had similar annealing temperatures, and guanine
and cytosine content as the other primers used in this assay. A BLASTn search was
also performed on this primer pair, to ensure there was no sequence similarity to N.
gonorrhoeae, or indeed to any other Neisseria spp.
The primers used for the multiplex assay in this study were carefully chosen.
Particular attention was paid to ensuring that the genes chosen as targets were highly
conserved among N. gonorrhoeae strains and were less likely to be affected by
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genetic exchange or recombination than some of the other less well-conserved genes
in the genome. The porA pseudogene for example has been shown to be highly
conserved among N. gonorrhoeae strains (Whiley et al, 2006a). In a study by Viscidi
and Demma, (2003), investigating the genetic diversity of housekeeping genes in 18
N. gonorrhoeae strains, it was found that there were only three nucleotide differences
in the pgil gene among the 18 strains at positions, 56, 85 and 84. The primers selected
here did not include regions of the gene where these polymorphisms occurred.
Particular attention was also paid to ensuring that each of the primer sequences
chosen was unique to the N. gonorrhoeae genome. This was achieved by performing
a BLASTn search of each of the primer sequences. This was important to minimise
the risk of amplification of non-gonococcal sequences, which would cause a false
positive result. These two aspects of primer design laid the foundation for a successful
assay.
As already outlined in table 4.1, section 4.3, a number of genes were
investigated as possible targets for this assay. Some of these genes were excluded as
they showed too much homology to other Neisseria spp. making it impossible to
select primers that would have exclusively amplified N. gonorrhoeae DNA. Other
potential primers investigated were excluded for various reasons such as that the
guanine and cytosine content would have made it difficult to select adequate primers
for a PCR assay. For example some of the sequences would have had high self
complementarity, or the sequences had unacceptable melting or annealing
temperatures, or the sequences would have been prone to the formation of secondary
structures which would have interfered with primer-template annealing, or finally that
the sequences had excessive numbers of repeats or long runs of a single bases which
could potentially cause mispriming.
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The abcZ gene was excluded as a potential target because only approximately
half of the gene showed homology between all the known sequences of the gene.
Within this region it was impossible to choose suitable primers that didn’t also display
homology with known N. meningitidis sequences. The adhC gene demonstrated up to
97% homology with some N. meningitidis sequences. One potential primer was
identified; however it proved difficult to identify a second. The adk gene was
excluded as this gene showed up to 95% homology with N. meningitidis sequences
and it also showed high homology with other Neisseria spp. such as N. mucosa, N.
cinerea, N. flavescens, and N. polysaccharea. The aroE gene again demonstrated high
homology with N. meningitidis, N. cinerea, N. flavescence and N. lactamica
sequences. Although one potentially useful primer was identified for this target it
proved difficult to identify a second primer. The carA gene consisted of a large
subunit and a small subunit. The large and small subunits demonstrated up to 95%
and 96% homology with some N. meningitidis strains, respectively. Each of the many
potential primers examined for this gene would have risked amplifying N.
meningitidis sequences. The cppB gene was excluded as a potential target as reference
was found in the literature of c/?/?7?-negative strains (Turn et al, 2005). The fumC gene
showed homologies of 95% and 93% to N. meningitidis and N. sub/lava sequences
respectively. Although one potentially useful primer was identified, it contained
excessive numbers of guanine and cytosine bases, and was therefore considered
unsuitable. The gdh gene was excluded as a target as it showed 100% homology with
a number of N. meningitidis sequences. The glnA gene was excluded as a possible
target as some of the known N. gonorrhoeae strains only showed homology within
less than half of the gene. Within that region, N. meningitidis, N. cinerea, N.
flavescence and N. lactamica demonstrated homologies of 97%, 95%, 88% and 93 %
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respectively. This made it impossible to select primers that would have amplified
gonococcal DNA exclusively. The gnd gene was also excluded as a target as some of
the known N. gonorrhoeae strains only showed homology over less than half of the
gene. Within that region it was impossible to choose primers that would have
exclusively amplified gonococcal DNA. The gpdhC gene demonstrated up to 98%
homology with some N. meningitidis strains making it impossible to identify primers
that would have exclusively amplified gonococcal DNA. The pdhC gene was
excluded because it was impossible to choose suitable primers from areas of the gene
that were conserved in all known gonococcal strains. The pilA gene demonstrated
complete homology to a N. meningitidis strain and was therefore excluded as a
potential target. The pip gene demonstrated up to 97% homology to some N.
meningitidis strains, it therefore proved impossible to select primers that would have
only amplified gonococcal DNA. The ppk gene demonstrated up to 96% homology
with some N. meningitidis strains. It was also apparent that there was some diversity
among gonococcal strains. Consequently it was impossible to select primers that
would have amplified all known gonococcal strains and not amplified N. meningitidis
strains. The pyrD and serC genes were excluded as potential targets for the same
reasons.
In the case of the pgi2 gene, two potentially suitable primers were identified
which would have produced a PCR product of 154 base pairs. Although some N.
meningitidis strains demonstrated up to 95% homology, two potential primers giving
a product size of 228 base pairs were identified in the gpdh gene. The pgilgQWQ
demonstrated up to 97% homology with known N. meningitidis strains and also
demonstrated diversity within gonococcal strains. Despite this, by selecting areas of
the gene that were unique to N. gonorrhoeae, it was possible to choose two primers
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which were eonserved among gonococcal strains and which did not appear in any
other Neisseria spp. sequences. These two primers produced a product of 174 base
pairs long. The pgm gene demonstrated up to 93% homology with known N.
meningitidis strains and also demonstrated diversity within gonococcal strains.
Despite this, it was possible to choose two primers that were conserved among
gonocoecal strains, which produced a PCR product 397 base pairs long. Although
these primers did show some similarities with N. meningitidis and N. cinerea they
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were sufficiently different to ensure that only gonococcal species would be amplified.
The and showed no homology to other Neisseria strains. Two primers were ehosen
which porA pseudogene demonstrated up to 86% homology with N. meningitidis
strains uniquely amplified gonococcal DNA producing a PCR product 260 base pairs
long.
Putative suitable primers had been chosen for five of the genes considered. It
was planned however, that the multiplex PCR assay would incorporate three targets;
therefore two further genes needed to be eliminated. The final three genes were
chosen so as to maximise the difference in size of PCR products so that three separate
bands would be clearly distinguishable on a 1.5% agarose gel. Pgm, which had the
largest product of 397 base pairs, was chosen for inclusion in the assay. The porA
pseudogene was chosen for inclusion, as the primer pair selected for this target
demonstrated no homology to other Neisseria spp. It was decided to exclude the gpdh
gene as a target, as it was felt that it was better to choose a primer pair that produced a
smaller PCR product to ensure the band produced on the agarose gel was
distinguishable from the porA band. It was decided to include the pgil gene as a target
rather than the pgi2 gene, as one of the primers for the pgi2 gene had a rather low
guanine and cytosine content. Thus the three target genes of pgm, pgil and porA were
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selected for inclusion in the multiplex assay. The pgm gene was however excluded at
a later stage due to problems distinguishing it from the internal control product on a
1.5% agarose gel due to the proximity of the two bands on the gel. If there were to be
an anomalous result for a sample where only one of the two targets, parA and pgil,
were amplified, the primers for the pgm target could easily be reintroduced into the
assay instead of the internal control to resolve such an anomaly. In such a case the
porA or pgil targets, which amplified in the original assay would act as an internal
control.
The multiplex assay designed in this study was found to be both highly
sensitive and specific. A positive result was obtained for each of the 34 N.
gonorrhoeae isolates tested and a negative result was obtained for each of the 17 non
gonococcal isolates (including 11 non-gonococcal Neisseria spp.) tested. This assay
therefore has a specificity and sensitivity of 100% for all 51 isolates included in the
study. This is very significant as there were no false positive or false negative results
obtained for the isolates tested. It should be noted however that it would be desirable
to validate this assay with a larger number of isolates from different geographic
locations. The results obtained in this study are, however, extremely promising. They
suggest that this assay might be suitable for routine screening for N. gonorrhoeae.
The PCR products from one of the N. gonorrhoeae isolates (isolate CUH 29)
were randomly selected for sequencing on the basis that products of the same
expected size were obtained for all N. gonorrhoeae isolates and for the internal
control. The sequences obtained were then entered in BLASTn to demonstrate that
their sequences were consistent with the corresponding known genes in Genbank. The
porA pseudogene products demonstrated 100% homology to accession number’s:
AJ223449.1, AJ223448.1, AJ223447.1, AJ223446.1, AJ010733.1, AJ010732.1,
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AE004969.1 and AF169417.1. The pgil gene products demonstrated 100% homology
with accession number’s: AF520296.1, AF520295.1 and AE002969.1. Thepgm
reverse gene products showed 100% homology with accession numbers’s:
CPOO 1050.1, AF520233.1, U02489.1, AE004969.1 and L23426.1. The pgm forward
gene products however showed 99% homology with each of these accession
numbers’s. They displayed one mismatch at position 340 where a cytosine base
appears in the sequenced product and a thymine base appears in the sequences
published in Genbank. When the chromatograph of the sequenced products is
examined however there is no cytosine peak and a very small thymine peak at this
position. It is therefore concluded that thymine is the correct base. In the case of the
internal control the forward sequence demonstrated between 85 and 95% homology to
published sequences and the reverse sequence demonstrated between 87 and 100%
homology. The lack of complete homology with all the published sequences was not a
concern as the primers included in this study were designed to be homologous to the
V. cholerae strain used in this study rather than all V. cholerae strains. When the
ompw PCR products were aligned there was one mismatch between a guanine and
cytosine base, see figure 4.13 in section 4.4.5. When the chromatographs for these
sequences were examined there appeared to be a double peak for a cytosine base and
a guanine base at this site in the forward sequence see figure 7.23 in the appendix
section. If the guanine base is corrected to a cytosine base the anomaly would be
resolved.
The homology shown by the sequenced products with published sequences in
GenBank demonstrates that the intended targets were amplified. The sequences were
not submitted to GenBank as they were partial gene sequences and they showed 100%
homology to published sequences of these genes.
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The limit of detection was determined by serially diluting extracted DNA from
the control N. gonorrhoeae (ATCC 3126) and by running the multiplex PCR assay on
this DNA. The limit of detection was found to be 5ng of DNA. This assay is therefore
capable of detecting very small amounts of target DNA this would be particularly
important for poorly-taken samples which may contain only a small amount of
organism. This ability to detect small amounts of the organism was further
demonstrated by spiking samples of chlamydia transport medium. It was
demonstrated that samples spiked with just one colony of N. gonorrhoeae were
detected successfully by this assay. This would suggest that this assay could be used
on the same samples collected when testing for Chlamydia trachomatis. This could
prove very useful as the same patient populations are often tested for both C
trachomatis and N. gonorrhoeae. A further study would be needed to validate the use
of this assay on such specimens. The additional work needed for this assay however
was not within the remit of this project.
The inability of NAAT to provide antimicrobial resistance data is a drawback
to the use of these systems for the routine diagnosis of gonococcal infection. However
antimicrobial testing of a subset of N. gonorrhoeae isolates would provide an
indication of the rates of resistance that would be expected in drugs routinely used to
treat N. gonorrhoeae infection. There have been a number of studies investigating the
use of molecular techniques for identifying antimicrobial resistance in N.
gonorrhoeae (Ameyama et al, 2002; Li et al, 2002; Zarantonelli et al, 1999; Katsumi
et al, 2006; Katsumi et al, 2004). A wide range of resistance mechanisms to various
antimicrobials are found among N. gonorrhoeae isolates as shown in table 1.4. The
penA and ponA genes, for example are involved in resistance to B lactam antibiotics,
the gyrA and parC genes are involved in quinlone resistance; the Mtr R gene is

r -r

'■

n.

78

involved in resistance to Azithromycin; the Pen B, Rps J and Mtr R genes are
associated with Tetracycline resistance, and the penA, penB and mtrR genes are
associated with cephalosporin resistance. It would therefore be difficult to include all
of them in an assay designed to detect N. gonorrhoeae.
As shown in figures 1.1. and 1.2. (section 1.2), resistance rates to many of the
drugs used in the treatment of gonococcal infections are increasing. It is therefore
important that routine surveillance of the sensitivities of isolates to routinely used
drugs is performed. This approach provides valuable information for empiric
treatment. The aim of gonococcal susceptibility testing is to establish effective
standardised treatments. Therefore a sufficient and representative sample of isolates
rather than all available gonococcal isolates may be sufficient to test for antibiotic
susceptibility. Such a sample population of isolates might be obtained by means of
targeted culture of selected samples. These might include patients with a positive
NAAT returning for their laboratory results and follow up treatment or, in the case of
an STI clinic setting, patients with positive microscopy (Whiley et al, 2006b). Patients
attending STI clinics such as that at the South Infirmary Victoria Hospital, Cork, who
have a direct positive Gram result, receive empiric therapy. The capacity to perform
culture would need to be retained by the laboratory, as patients who experience
treatment failure require susceptibility testing to be performed.
The main aim of this study was to design a multiplex PCR assay to detect N.
gonorrhoeae. The design of primers specific for the N. gonorrhoeae porA and pgil
genes, and incorporating them along with an internal control in a multiplex assay,
proved 100% specific and the method designed in the study was 100% sensitive to
detection limit of 5ng of DNA using strains isolated from patients samples and using
known control strains. In addition, samples of Chlamydia transport media, which were
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spiked with N. gonorrhoeae, were detected successfully. The assay described here
works very well; it detects two separate genes of N. gonorrhoeae ensuring that
isolates are accurately detected while minimising the risk of false positive results. The
inclusion of an internal control also eliminates the risk of false negatives due to
inhibitory substances. Each of the objectives set out at the start of the study were
therefore achieved.
Following a recent literature search there is only one assay, recently published,
which uses two different genetic targets in the one reaction for the detection of N.
gonorrhoeae (Goire et al, 2008). The genes targeted are the ForA pseudogene and
opa gene. This assay was found to have a sensitivity of 100% and a specificity of
99.3%. The sensitivity and specificity rates were however calculated by comparing
the duplex assay with three monoplex assays, one of which used the same porA
pseudogene primers as the duplex assay, and a second which also used the same opa
gene primers as the duplex assay (Goire et al, 2008).
Further work on the assay described in this project could involve adapting it
for use in a real time PCR system. This would make it more attractive for use in
clinical laboratories as the turnaround time would be reduced. Another avenue which
could be explored may involve the possibility of developing a hybridisation detection
system for use in conjunction with the conventional PCR assay in an open platform
system similar to the BioEnteric faecal pathogen detection system recently developed
by Serosep (www.bioenteric.com). Alternatively, a commercial biotechnology
company could develop the assay further to produce an automated system into which
the assay could be incorporated. Such systems would be attractive and user-friendly to
the clinical microbiology laboratory.
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Table 7.1. The identifications of clinical and control isolates using
conventional tests Gram, oxidase, catalase and API.
Isolate
API
Gram Oxidase Catalase
ID
+
+
1
GNDC
1001
N gonorrhoeae
+
+
2
GNDC
1001
N gonorrhoeae
+
3
GNDC
1001
N gonorrhoeae
+
+
4
GNDC
1001
N gonorrhoeae
+
+
5
GNDC
1001
N gonorrhoeae
+
+
6
GNDC
1001
N gonorrhoeae
+
+
7
GNDC
1001
N gonorrhoeae
+
+
8
GNDC
1002
N. meningitidis
+
+
9
GNDC
1001
N gonorrhoeae
+
10
GNDC
1001
N gonorrhoeae
+
+
11
GNDC
1001
N gonorrhoeae
+
+
12
GNDC
5003
N. meningitidis
+
+
13
GNDC
5002
N. meningitidis
14
N/A*
N/A*
N/A
N/A
N/A
+
+
15
GNDC
1001
N gonorrhoeae
16
N/A
N/A
N/A
N/A
N/A
+
+
17
GNDC
1001
N gonorrhoeae
+
+
18
GNDC
1001
N gonorrhoeae
+
+
19
GNDC
1002
N meningitidis
+
+
20
GNDC
1001
N gonorrhoeae
21
N/A
N/A
N/A
N/A
N/A
+
+
22
GNDC
1001
N gonorrhoeae
+
+
23
GNDC
1001
N gonorrhoeae
+
+
24
GNDC
1001
N gonorrhoeae
+
+
25
GNDC
1001
N gonorrhoeae
+
+
26
GNDC
5002
N. meningitidis
+
27
GNDC
5002
N. meningitidis
+
+
28
1001
GNDC
N gonorrhoeae
+
29
GNDC
1001
N gonorrhoeae
+
+
30
GNDC
1001
N gonorrhoeae
+
+
31
GNDC
1001
N gonorrhoeae
+
+
32
GNDC
1001
N gonorrhoeae
+
+
33
GNDC
1001
N gonorrhoeae
+
+
34
GNDC
1001
N gonorrhoeae
+
+
5041
35
GNDC
N. lactamica
+
+
36
GNDC
7001
N. sicca
+
+
37
GNDC
1001
N gonorrhoeae
+
+
38
GNDC
1001
N gonorrhoeae
+
39
GNDC
1001
N gonorrhoeae
+
+
40
GNDC
1001
N gonorrhoeae
+
+
41
GNDC
1001
N gonorrhoeae
+
+
42
GNDC
7101
N.flavescens
+
+
43
GNDC
0001
N.cinerea
+
+
44
GNDC
5002
N. meningitidis
+
+
45
GNDC
1001
N gonorrhoeae
+
46
GNDC
1001
N gonorrhoeae
+
-f
47
GNDC
1001
N gonorrhoeae
+
+
48
GNDC
1001
N gonorrhoeae
A
N/A
GPC
N/A
N/A
group B streptococci.
GPC
B
N/A
N/A
N/A
Enterococcus spp.
GPC
+
N/A
C
N/A
coagulase neg staph..
D
GNB
N/A
1215773
K. pneumoniae.
GBS
Extracted DNA.
group B streptococci.
TR+
Extracted DNA.
group A streptococci
Note: * = Not Applicable.
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Figure 7.1. Nanodrop readout of the DNA extracted from a
selection of isolates.
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Figure 7.2. The DNA extracted from a selection of isolates on a 1% Agarose
gel.
Table 7.2. Positions of isolates in gel in figure 7.2. See table 1 for identities
of isolates

Lane
1
2
3
4
5
6
7
8
9
10
11
12
13
M.

Top line.
Isolate no.
30
29
26
25
24
22
19

Bottom line
Isolate no.
44
41
41A
40
39
38
37

18
17
12
11
10
8
Molecular
Weight marker.
Grade III

36
35
34
33
32
31

Lane
14
15
16
17
18
19
M

Top line.
Isolate no.
6
5
4
3
2
1
Molecular Weight
marker. Grade III
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Figure 7.3. Result of Entrez investigation for the locus tag
NGO0719 of the pgi I gene.
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Figure 7.4. BLASTn search of entire pgil gene. There are
four known sequences of this gene in GenBank.
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Figure 7.5. Primers selected for the pgil gene with the aid of
the primer 3 programme. Note: The arrows (<) indicate the
position of the primers within the sequence of the gene.

100

Figure 7.6. BLASTn search of the pgil forward primer. The sequence of
this primer matches perfectly to each of the known sequences of the pgil
gene in N. gonorrhoeae.
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Figure 7.7. BLASTn search of the pgil reverse primer. The sequence
of this primer matches perfectly to each of the known sequences of the
pgil gene in N. gonorrhoeae.
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Figure 7.8. BLASTn search of entire porA gene. There are eight
known sequences of this gene in GenBank.
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Figure 7.9. Primers selected for the porA gene with the aid of
the primer 3 programme.
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Figure 7.10. BLASTn search of the porA forward primer. The
sequence of this primer matches perfectly to each of the known
sequences of the porA gene in N. gonorrhoeae.
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Figure 7.11. BLASTn search of the porA reverse primer. The
sequence of this primer matches perfectly to each of the known
sequences of the porA gene in N. gonorrhoeae.
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Figure 7.12. Multiplex PCR of isolates 1-10 (see table 7.1). Lane 1, negative
control. Lane 2, positive control. Lane 3, isolate 10, N. gonorrhoeae. Lane 4, isolate
9, N. gonorrhoeae. Lane 5, isolate 8, N. meningitidis. Lane 6, isolate 7, N.
gonorrhoeae. Lane 7, isolate 6 N. gonorrhoeae. Lane 8, isolate 5, N. gonorrhoeae.
Lane 9, isolate 4, N. gonorrhoeae. Lane 10, isolate 3, N. gonorrhoeae. Lane 11,
isolate 2, N. gonorrhoeae. Lane 12, isolate 1, N. gonorrhoeae. M=molecular weight
marker Grade V.
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Figure 7.13. Multiplex PCR of isolates 11-24 (see table 7.1). Lane 1, isolate 24, N.
gonorrhoeae. Lane 2, isolate 23, N. gonorrhoeae. Lane 3, isolate 22 N. gonorrhoeae.
Lane 4, isolate 20, N. gonorrhoeae. Lane 5, isolate 19, N. meningitidis. Lane 6 isolate
18, N. gonorrhoeae. Lane 7, isolate 17, N. gonorrhoeae. Lane 8, isolate 15, N.
gonorrhoeae. Lane 9, isolate 13, N. meningitidis. Lane 10, isolate 12, N. meningitidis.
Lane 11, isolate 11, A^. gonorrhoeae. M= molecular weight marker Grade V.
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Figure 7.14. Multiplex PCR of isolates 25-33 (see table 7.1). Lane 1,
negative control. Lane 2, positive control. Lane 3, isolate 33, N.
gonorrhoeae. Lane 4, isolate 32, N. gonorrhoeae. Lane 5, isolate 31, A^.
gonorrhoeae. Lane 6, isolate 30, N. gonorrhoeae. Lane 7, isolate 29, N.
gonorrhoeae. Lane 8, isolate 28, N. gonorrhoeae. Lane 9, isolate 27, N.
meningitidis. Lane 10, isolate 26, N. meningitidis. Lane 11, isolate 25,
N. gonorrhoeae. M=molecular weight marker grade V.
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Figure 7.15. Multiplex PCR of isolates 34-44 (see table 7.1). Lane 1,
isolate 44, N meningitidis. Lane 2, isolate 43, N. cinerea. Lane 3, isolate
42, N. flavescens. Lane 4, isolate 41, A^. gonorrhoeae. Lane 5, isolate 40,
N. gonorrhoeae. Lane 6, isolate 39, N. gonorrhoeae. Lane 7, isolate 38,
N. gonorrhoeae. Lane 8, isolate 37, N. gonorrhoeae. Lane 9, isolate 36,
N. sicca. Lane 10, isolate 35, N. lactamica. Lane 11, isolate 34, N.
gonorrhoeae. M=moleeular weight marker grade V.
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Figure 7.16. Multiplex PCR of isolates 45-48, A-D, GBS and TR+ (see
table 7.1). Lane 1, TR+. Lane 2, GBS. Lane 3, isolate D, K. pneumoniae.
Lane 4, isolate C, Coagulase negative Staphylococci. Lane 5, isolate B,
Enterococcus spp. Lane 6, isolate A, group B Streptococci. Lane 7,
isolate 48, N. gonorrhoeae. Lane 8, isolate 47, N. gonorrhoeae. Lane 9,
isolate 46, N. gonorrhoeae. Lane 10, isolate 45, N. gonorrhoeae.
M=moleeular weight marker grade V.
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Figure 7.17. Chromatograph of dqH gene product forward sequence
from isolate CUH 29.
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Figure 7.18. Chromatograph of dqH gene product reverse sequence
from isolate CUH 29.
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Figure 7.19. Chromatograph ofporA gene product forward sequence from
isolate CUH 29.
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Figure 7.20. Chromatograph of porA gene product reverse sequence from
isolate CUH 29.
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Figure 7.21. Chromatograph of p^m gene product forward sequence
from isolate CUH 29.
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Figure 7.22. Chromatograph of pgm gene product reverse sequence
from isolate CUH 29.
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Figure 7.23. Chromatograph of ompW gene product forward sequence
from the internal control.
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Figure 7.24. Chromatograph of ompWgene produet reverse sequence from
the internal control.

